

Title: How demographic factors matter for antimicrobial resistance – quantification of the patterns and impact of variation in prevalence of resistance by age and sex.

Authors:

Naomi R Waterlow¹

Ben S Cooper²

Julie V Robotham³

Gwenan M Knight^{1,4*}

* corresponding author

Affiliations

1. Centre for Mathematical Modelling of Infectious Diseases, Department of Infectious Disease Epidemiology, EPH, London School of Hygiene and Tropical Medicine, WC1E 7HT
2. Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
3. HCAI, Fungal, AMR, AMU and Sepsis Division, UK Health Security Agency, London, UK.
4. AMR Centre, London School of Hygiene and Tropical Medicine, WC1E 7HT

Abstract

Background

Antibiotic usage, contact with high transmission healthcare settings as well as changes in immune system function all vary by a patient's age and sex. Yet, most analyses of antimicrobial resistance (AMR) ignore demographic indicators and provide only country level resistance prevalence values.

In this work we use routine surveillance data on serious infections in Europe to characterise the importance of age and sex on incidence and resistance prevalence patterns for 33 different bacteria and antibiotic combinations. We fit Bayesian multilevel regression models to quantify these effects and provide estimates of country-, bacteria- and drug-family effect variation.

Results

At the European level, we find distinct patterns in resistance prevalence by age that have previously not been explored in detail. Trends often vary more within an antibiotic family than within a bacterium: clear resistance increases by age for methicillin resistant *S. aureus* (MRSA) contrast with a peak in resistance to several antibiotics at ~30 years of age for *P. aeruginosa*. This diverges from the known, clear exponential increase in infection incidence rates by age, which are higher for males except for *E. coli* at ages 15-40.

At the country-level, the patterns are highly context specific with national and subnational differences accounting for a large amount of resistance variation (~38%) and a range of associations between age and resistance prevalence. We explore our results in greater depths for two of the most clinically important bacteria–antibiotic combinations. For MRSA, age trends were mostly positive, with 72% of countries seeing an increased resistance between males aged 1 and 100 and more resistance in males. This compares to age trends for aminopenicillin resistance in *E. coli* which were mostly negative (males: 93% of countries see decreased resistance between ages 1 and 100) with more resistance in females. A change in resistance prevalence between ages 1 and 100 ranged up to ~0.46 (95% CI 0.37 – 0.51, males) for MRSA but varied between 0.16 (95% CI 0.23-0.3, females) to -0.27 (95%CI -0.4 - -0.15, males) across individual countries for aminopenicillin resistance in *E. coli*.

Conclusion

Prevalence of resistance in infection varies substantially by the age and sex of the individual revealing gaps in our understanding of AMR epidemiology. These context-specific patterns should now be exploited to improve intervention targeting as well as our understanding of AMR dynamics.

Introduction

Antimicrobial resistance (AMR) is a global public health priority (1). Understanding how it will be affected by the dramatic demographic shifts that are underway worldwide is a key knowledge gap. The WHO has estimated that one in five people in the world will be aged 60 years or older by 2050 (2). Incidence of bacterial infections is known to increase by age (3) and vary by sex, though the exact trends are rarely quantified. The higher burden of infection in older age groups, results in higher antibiotic exposure and higher contact with healthcare settings which are known hotspots of resistant bacteria transmission. However, there is not a simplistic increase in resistance in all pathogens by age. Determining how the above interact to drive the dynamics of drug resistant infections (DRI) is a vital part of understanding how best to tackle AMR.

Age- and sex-disaggregated data are collected by most routine AMR surveillance schemes. The WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS) requests age- and sex-stratifications from reporting countries (4). However, this data is not openly available at low age-band segregation (i.e. more than 4 broad categories) with sex – for example not from the WHO GLASS dashboard (5) nor the ECDC Surveillance ATLAS dashboard (6) nor the US Centres for Disease Control and Prevention (7). The recent WHO reports also have no presented analysis of how resistance prevalence varies by these demographic factors (8,8). The dramatic, often exponential, increase in infection incidence with older age has been reported in several places (9–12) as well as the differences by sex (13). However, how this burden is split into resistant or susceptible infection by patient age and sex is relatively rarely reported. Multiple attempts to predict AMR burden are hampered by a basic lack of surveillance data and yet factors such as sex and age are variables that are nearly always available for analysis.

The importance of age being linked to variation in AMR has been graphically explored before for Europe (14) and more comprehensively in single setting studies (e.g. (15–17)). Complex statistical analysis based on the Global Burden of Disease methods have produced age- and sex-specific estimates of mortality rates by European country attributable to all AMR (18). However, to our knowledge there has been no comprehensive analysis of the relationship between age and AMR in infection between bacteria across multiple countries. This is despite the wide awareness of age-specific effects for infection that have only been emphasised by the COVID-19 pandemic (19).

Despite awareness of the importance of sex for many risk factors for infectious diseases (e.g. HIV) and bacterial infections such as urinary tract infections, how prevalence of drug-resistant infection (DRI) varies between the sexes (and genders) is vastly underexplored in the literature (20). This is despite many studies of single bacteria or syndromes finding a difference in resistance prevalence in infection between the sexes (21–26). In 2018, the WHO called for countries to take the first step to better considering “gender and equity” in National Action Plans for AMR (27), which have historically lacked such considerations (e.g. in Southeast Asia (28)).

Prevalence of resistance in infection is known to vary between countries (5,8) and sub-nationally, by factors such as governance and deprivation level (29–31). This may be linked in part to differences in healthcare structures and antibiotic usage (32,33). Other national level healthcare structures and cultural differences are likely to have wider impacts on AMR patterns by age and sex. For example, variation in birth rates by age between countries (34), as well as type of birth (vaginal vs caesarean)(35) will impact the type of antibiotic as well as healthcare exposures in women. Determining how these cultural factors interplay with biological factors as we age and across sexes is key to understanding the complexity of AMR interventions.

Here, we use large, routinely collected data on bloodstream infection to explore generalised trends in antibiotic resistance prevalence in infection by age and sex in Europe. It is vital for antibiotic prescribing to account for local trends in resistance, as well as how they vary by age and sex. We do not wish to oversimplify any trends in AMR by age or sex – risk factors, previous prescribing as well as contact with high-risk transmission settings such as hospital or long-term care facilities will all influence individual level risk of AMR infection. However, our ecological analysis deepens our understanding of AMR epidemiology in Europe and suggests testable hypotheses about the underlying cultural and biological factors driving differences in resistance by age and sex.

Methods

Our analysis was in three stages – firstly we explored the trends in resistance prevalence by age and sex across Europe, and secondly estimated and quantified the incidence of infection for each of the bacterial species by age and sex. Thirdly, we quantified the proportion of those infections that were due to resistant bacteria for different bacteria-antibiotic combinations by age and sex, country and sub-national indicator (laboratory). All code is available in online repository (36). Patient level data is available upon request from the European Antimicrobial Resistance Surveillance Network (EARS-Net) from the Surveillance System (TESSy) (37).

We show the overall results for trends and incidences across all bacteria-antibiotic combinations, highlighting bacteria-antibiotic combinations of interest, then demonstrate specific age-associated results using two of the clinically most important bacteria-antibiotic combinations: MRSA and *E.coli* – aminopenicillins (amoxicillin and ampicillin).

Data

We analysed individual European Antimicrobial Resistance Surveillance Network (EARS-Net) patient level data from the Surveillance System (TESSy), provided by Austria, Belgium, Bulgaria, Cyprus, Czechia, Germany, Denmark, Estonia, Greece, Spain, Finland, France, Croatia, Hungary, Ireland, Iceland, Italy, Lithuania, Luxembourg, Latvia, Malta, Netherlands, Norway, Poland, Portugal, Romania, Sweden, Slovenia, Slovakia and the United Kingdom and released by ECDC (37). Countries were anonymised using a random 3-letter code, which is used throughout the paper. This surveillance network collects routine clinical antimicrobial susceptibility testing (AST) results, alongside some patient data, including sex and age, from EU and EEA countries (we use the term European throughout). The general quality and comparability of the data is evaluated through a standard annual external exercise (38) with the AST results taken from shared protocols (39,40). The data consists of AST for the first blood and/or cerebrospinal fluid isolate (< 0.7% of this dataset) of every patient with an invasive infection associated with one of the pathogens under surveillance. Levels of coverage are discussed and explored in the calculation of incidence (see below and Appendix S1, section 3). In our main analysis we exclude individuals aged 0, due to their stark difference in immune dynamics and contact patterns, but run a sensitivity analysis including them.

Individual patient data from EARS-Net was extracted with information on the age and sex of the patient, resistance presence, laboratory code, year of sample and reporting country. For incidence calculations we included all isolates with recorded age and sex values, for those aged one or older (89% of the original 3,549,617 isolates). For resistance prevalence calculations, we used the susceptibility test result data for 2015-2019 in those aged one or older, with data on age and sex. This resulted in a dataset of susceptibility results for 17 antibiotics, 8 bacteria in 29 countries (Appendix S1, section 2). The number of isolates provided from each of the 29 countries varied between 15,298 and 619,648 (Appendix S1, section 2). An analysis on missing data both in terms of (a) distribution of age and sex within those not tested for resistance and (b) resistance prevalence in those without age and sex information is in (Appendix S1, section 2).

We used the United Nations subregion definitions, except for Cyprus, which was grouped with Southern Europe (instead of being the only Western Asia country). Some susceptibility data grouped results for multiple antibiotics together: “aminopenicillins” are ampicillin or amoxicillin, “3G cephalosporins” are cefotaxime, ceftriaxone or ceftazidime, “fluoroquinolones” are ciprofloxacin, levofloxacin or ofloxacin, “aminoglycosides” are gentamicin or tobramycin, “macrolides” are azithromycin, clarithromycin or erythromycin, “penicillins” are penicillin or oxacillin, “carbapenems” are imipenem/meropenem. See ECDC report Table 1 for further bacterial-antibiotic specific pairing

(41). Where we had multiple susceptibility results for individual antibiotic within a drug family (beta-lactam) we grouped antibiotics by AWaRE classifications (42). We follow the ECDC analysis and assume “sex” rather than “gender” was recorded in the data.

(1) *Prevalence of resistance in infection by age and sex*

Using the cleaned data we explored variation in patterns in aggregated sex- and age-based resistance prevalence in infection at the European and subregional levels.

(2) *Incidence of infection by age*

Following the methods of Cassini et al (43) (Appendix S1, section 3&4), it was assumed that all eligible invasive isolates are reported by the participating laboratories. The estimated coverage of these laboratories was then used as an inflation factor to calculate the number of BSIs. Data for country coverage was taken from previous EARS-Net reports and the Cassini et al estimates for 2015, 2018, 2019 and 2020. The incidence of infection in each of these years was calculated by dividing the number of isolates from patients in each 5yr age and sex band by the corresponding population sizes from the World Bank DataBank (44), up to a pooling of all those aged 80 or older.

(3) *Trend analysis for resistance proportion by age*

Multilevel regression models were fitted to the ECDC data to understand the impact of including age and sex in models of resistance prevalence. We used a Bayesian framework using the R package *brms* (45) and ran models using the No U-turn Sampling separately for each bacteria-antibiotic combination, using data from 2015-2019. Individual level data was aggregated to group level by country, laboratory code, sex, age and year of sample and standardised as appropriate (Appendix S1, section 5). Models were considered converged if the Rhat was <1.1, a sufficient Effective Sample Size for each parameter was reached and we checked for divergent transitions (Appendix S1 section 5). We initially ran 3000 iterations and extended this to 5000 for those models that had not reached convergence at this point. Country and laboratory code were included as substantial variation was observed between them (Appendix S1, section 5). Only the sexes “male” and “female” were included in the analysis and records missing age or sex were dropped.

Thus, for each bacteria-antibiotic combination, our data consisted of multiple groupings of individual samples of a bacterium tested for resistance to that antibiotic. Each grouping i had a unique combination of country (c), laboratory code (l), sex, age and year of sample and hence a linked number of samples (n) and proportion resistant (p).

For each bacteria-antibiotic combination we ran a multi-level logistic regression model to predict the probability of an isolate being resistant to the antibiotic, assuming a Binomial distribution over the number of samples in each grouping. Our model included both age and sex terms (Equations 1:2).

	$y_{c,l,i} \sim \text{Binomial}(n_{c,l,i}, p_{c,l,i})$	(1)
	$p_{c,l,i} = \beta_0 + \beta_t * t_i + \beta_a * age_i + \beta_{a^2} * age_i^2 + \beta_g * sex_i + \beta_{ag} * age * sex_i + v_c + v_{ca} * age_i + u_{c,l} + \epsilon_{c,l,i}$	(2)

Where y is the resistance variable, taking a value of 0 or 1, n is the number of samples and p the probability of the sample being found to be resistant (NAs were excluded, Appendix S1, section 5). The subscripts c , l and i denote country, laboratory code and grouping level. β_0 is the overall intercept, β_t is slope coefficient for time and t is year. $\epsilon_{c,l,t}$ is the residual error, $u_{c,l}$ is the level-2 random error on laboratory code and v_c is the level-3 random error on country. β_a is the age effect coefficient,

β_{a^2} is the age squared effect coefficient and ν_{ca} is the country level age effect coefficient. β_g is the sex effect coefficient and β_{ag} is the sex and age interaction coefficient. All random errors are assumed to be normally distributed, and we assume flat priors on all covariates in the main analysis, but run a sensitivity analysis with weakly informative regularising priors. We did not use weakly informative priors for the main analysis, as we had no prior information on what the parameter values should be.

To determine an overall impact of age for each bacteria-antibiotic combination and country, we calculated the difference in proportion resistant between individuals aged 1 and those aged 100, using the posterior predictions from the model fit. We did this across all posterior samples, from which we calculated the median and 95% quantiles.

Sensitivity analysis

We explored further data disaggregation of incidence by patient location when the sample was taken (inpatient vs. outpatient and the hospital unit or ward type e.g. haematology or emergency department) For incidence analysis, we explored varying the inflation factor for the incidence of infection to check robustness of age and sex patterns.

For the modelling analysis, we explored including samples from individuals aged, including regularising priors and using a model selection-based philosophy. These sensitivity analyses were run for MRSA.

Ethics

This analysis of patterns of resistance in samples taken as part of routine surveillance was approved by the London School of Hygiene and Tropical Medicine Ethics board (ref 28157).

Results

European level

At the European level, there were clear non-linear differences in the prevalence of resistance in infection by age and sex for different bacteria-antibiotic combinations (Figure 1). These patterns were robust across subregions of Europe (Appendix S2, section 1). However, prevalence of resistance was generally higher in Southern and Eastern Europe, with stronger age-related trends (e.g. for methicillin resistance in *S. aureus* and across *Acinetobacter spp.*). The age-associated patterns varied more within drug-families than within certain bacteria (patterns within each colour are more different than within each row of Figure 1). For example, patterns of resistance across drug families were highly similar for some bacteria such as *Acinetobacter* species (Figure 1) whilst there was substantial variation within resistance proportions by age for fluroquinolones (blue data, Figure 1). Sex has little impact on many of the age-related trends except for *Acinetobacter* species at younger ages, and *E. coli* and *Klebsiella* at higher ages (Figure 1).

European level (2015-2019)




Figure 1: Trends in resistance prevalence vary by antibiotic, bacteria and demographic factors across Europe. The proportion of isolates tested (y axis) that are resistant to each antibiotic (column) within drug families and AWaRE groupings (colour) for each bacteria (row) is shown for all European data over 2015-2019 by age (x axis). Data is shown as points with number of samples indicated by size of point. Shaded areas are 95% confidence intervals around the LOESS fit line by sex (linetype and shade). AWaRE groupings were used here to better distinguish clinically important subsets within the beta-lactam family.

Incidence

As expected, across Europe, bloodstream infection incidence substantially increased with age with clear differences between the sexes (Figure 2). Men had a higher incidence of infections from approximately age 35 onwards, except for *E. coli* between ages 15 and 40 where women had a higher incidence. These patterns were robust at the country level and over time (Appendix S2, section 2). Differences in infection incidence between the pathogens reflect the overall burden in infection, with ranking incidence rates being (from highest): *E. coli*, *S. aureus*, *K. pneumoniae*, *E. faecium*, *P. aeruginosa*, *E. faecalis*, *S. pneumoniae*, *Acinetobacter species*.




Figure 2: Incidence of bloodstream infections per 100,000 population in 2019 across European countries for 8 bacterial pathogens split by (A) sex and bacteria for the first 50yrs of life and (B) sex (panel) and bacteria (colour) lifelong. Shaded areas are 95% confidence intervals using a LOESS fit. Infections in individuals younger than 0 are excluded, and those aged 80 and older are pooled into the 80yr data point.

The combination of these age-related trends in number of infections (Figure 2) with those in proportion resistant (Figure 1) lead to exponential increases in the number of resistant infections with age, as would be expected (Appendix S2, section 3) for all bacteria-antibiotic combinations.

Resistance prevalence

Our logistic model converged for 33 bacteria-antibiotic combinations (92%) (Appendix S2, section 4) and supported clear benefits of including age in predictions of resistance in infection, with substantial effects for at least one of age, age² or the interaction between age and sex (Table 1). Sex had less of a clear importance for many bacteria-antibiotic combinations, with at least one of the sex intercept or interaction terms being substantial for 19 of the 33 bacteria-antibiotic combinations. Full results for all bacteria-antibiotic combinations can be found in Appendix S3.

Table 1: Heatmap of the values of the fixed effect parameters for each bacteria-antibiotic model. Orange indicates a positive effect and blue indicates a negative effect (in both cases, where the 95% credible intervals of the posterior parameter estimate do not cross 0). Grey indicates no effect (i.e. posterior CI's cross 0). An equivalent table with the parameter values can be found in the supplement (Appendix S2, section 4). (m) indicates that the parameter is the coefficient for males.

Bacteria	Antibiotic	year	age	age ²	sex(m)	Age:sex(m)
<i>Acinetobacter species</i>	Amikacin	Grey	Orange	Blue	Grey	Grey
	Aminoglycosides	Blue	Orange	Blue	Orange	Grey
	Carbapenems	Grey	Orange	Blue	Grey	Grey
	Fluroquinolones	Blue	Orange	Blue	Orange	Grey
<i>Enterococcus faecalis</i>	High-level aminoglycoside	Blue	Orange	Blue	Grey	Grey
	Vancomycin	Blue	Orange	Blue	Grey	Grey
	Aminopenicillins	Orange	Orange	Blue	Grey	Grey
	High-level aminoglycoside	Blue	Orange	Blue	Grey	Grey
<i>Escherichia coli</i>	Amikacin	Grey	Grey	Orange	Orange	Grey
	Aminoglycosides	Blue	Grey	Grey	Orange	Blue
	Aminopenicillins	Blue	Blue	Orange	Orange	Blue
	Carbapenems	Orange	Blue	Grey	Orange	Grey
	Fluroquinolones	Blue	Orange	Blue	Orange	Blue
	Third-generation cephalosporins	Orange	Grey	Grey	Orange	Blue
	piperacillin-tazobactam	Blue	Grey	Grey	Orange	Blue
<i>Klebsiella pneumoniae</i>	Amikacin	Blue	Orange	Blue	Grey	Grey
	Aminoglycosides	Blue	Grey	Blue	Grey	Orange
	Carbapenems	Orange	Orange	Blue	Orange	Grey
	Ertapenem	Orange	Orange	Blue	Orange	Grey
	Fluroquinolones	Orange	Orange	Blue	Orange	Orange
	Third-generation cephalosporins	Grey	Grey	Blue	Orange	Orange
	piperacillin-tazobactam	Orange	Orange	Blue	Grey	Orange
<i>Pseudomonas aeruginosa</i>	Amikacin	Blue	Orange	Blue	Grey	Grey
	Aminoglycosides	Blue	Orange	Blue	Grey	Grey
	Carbapenems	Blue	Orange	Blue	Grey	Grey

	Ceftazidime					
	Fluoroquinolone					
	piperacillin-tazobactam					
<i>Staphylococcus aureus</i>	Fluoroquinolone					
	MRSA *					
	Rifampicin					
<i>Streptococcus pneumoniae</i>	Macrolide					
	Penicillins					

*primarily indicates oxacillin or cefoxitin resistance, but other markers are accepted for oxacillin, if oxacillin was not reported. See protocol for details (39).

Model analysis: examples

For MRSA, most countries (e.g. for males, 72%, 21/29 countries) had a positive trend with age (Figure 3), with a higher proportion of samples being resistant at age 100 than age 1 (Figure 3). The magnitude of this difference varied but reached a maximum difference in proportion of ~ 0.46 (95% quantile 0.37 – 0.51, country PUB) between males aged 1 and 100. Country level effects (panels, Figure 3) as well as laboratory (subnational) effects (lines, Figure 3) were highly important in capturing proportion resistant by age. There were also significant sex effects in both the intercept and age-slope terms for MRSA, which resulted in an increased age-impact in males (Figure 3).

Bacteria: *Staphylococcus aureus*, Antibiotic: MRSA (oxacillin or cefoxitin)




Figure 3: Model analysis for MRSA. A) Model parameters. B) Change in proportion resistant between ages 1 and 100 for each country and sex, with the point indicating the median and the error bars the 95% quantiles. C) Data (points) and model predictions (lines) with 95% CIs (ribbons) for the two sexes (rows) for the most extreme (left&right columns) and the middle country (middle column) estimated age slope. Each country has two lines, depicting the predictions for the most extreme

laboratories in the country. Data sample size is grouped across years and laboratories. MRSA primarily indicates oxacillin or ceftoxitin resistance, but other markers are accepted for oxacillin, if oxacillin was not reported. See protocol for details (39). Country labels are a random anonymised three letter code used for this analysis only.

For aminopenicillin (amoxicillin and ampicillin) resistance in *E.coli* we also see age effects across countries, however for this bacteria-antibiotic combination the age trend is mostly negative (males, 93%, 27/29 countries), with a lower proportion resistant with age. The magnitude of the age effect varied from 0.16 (95% quantiles 0.12 – 0.20, country BZT, female) to -0.27 (95% quantiles -0.4 - -0.15, country ABO, male). As with MRSA, substantial country and laboratory variation is observed (Figure 4). There is also a significant sex effect (Figure 4): we found, across ages, a higher proportion resistant in females.




Figure 4: Model analysis for *E.coli*, aminopenicillin resistance. A) Model parameters. B) Change in proportion resistant between ages 1 and 100 for each country and sex, with the point indicating the median and the error bars the 95% quantiles. C) Data (points) and model predictions (lines) with 95% CIs (ribbons) for the two sexes (rows) for the most extreme (left&right columns) and the middle country (middle column) estimated age slope. Each country has two lines, depicting the predictions for the most extreme laboratories in the country. Data sample size is grouped across years and laboratories. Country labels are random anonymised three letter code used for this analysis only.

Model analysis: general results

Whilst the two bacteria-antibiotic samples chosen above show substantial trends, there are many bacteria-antibiotic combinations where no age or sex trend is seen, or where there is little cross-country variation (completely overlapping confidence intervals when looking at the age 1 – 100 change) (Appendix S2, section 5). Additional bacteria-antibiotic combinations where a > 5% change in resistance proportion for multiple countries was seen include third-generation cephalosporin resistance in *E coli* and *K. pneumoniae*, fluoroquinolone resistance in *E coli*, *K. pneumoniae*, and *S.*

aureus, aminoglycoside resistance in *E. coli* and *K. pneumoniae*, and carbapenem resistance in *P. aeruginosa*. The latter is relatively stable at ~-10% across countries, whilst others have large variability. There is also substantial variation between different bacteria-antibiotic combinations within countries.

Looking across bacteria-antibiotic combinations, age-related trends were seen across drugs for *Acinetobacter* species (positive, both sexes), *E.coli* (positive, female) and *Pseudomonas aeruginosa* (negative, both sexes) (Figure 5A), although for these the majority were not significant at the 95% level, and have relatively small impacts. No clear age-related trends were linked to Gram stain, nor within antibiotic (or antibiotic families) were seen in our modelling results (Figure 5B), further emphasising the trends seen at the European level.




Figure 5: Change in proportion of samples resistant between age 1 and 100, A) by bacteria and B) by drug and drug family. The dashed line indicates 0.

Sensitivity analysis

Analysis of infection incidence by patient location when the sample was taken revealed large differences between countries across Europe likely linked to differences in healthcare systems and reporting protocols (Appendix S2, sections 6&7). Hence, we could not here explore resistance prevalence further by these differences. Age and sex patterns in incidence were robust to using the minimum surveillance coverage values (Appendix S2, section 8).

Modelling sensitivity analyses showed little effect of including samples from individuals aged 0 or from including regularising priors (Appendix S2, sections 9 & 10). Our model selection sensitivity analysis showed that even with the different philosophical approach, the model used in the main analysis was the preferred model (Appendix S2, section 11).

Discussion

Our comprehensive quantification of the strong ecological relationships between age and sex with resistance prevalence in bloodstream infection (BSI) across Europe highlights novel relationships not previously studied and suggests that such differences should be considered in AMR research and policy. Whilst there are limited previous studies looking at age and sex in the context of AMR, these do not provide their estimates of the relationships as output (18) or are limited to explorations in specific settings or bacteria (15,24,46–48). The only previous report considering age differences in detail focuses only on 6 bacteria-antibiotic combinations in 5 year age bands, and shows similar trends as we do (14) but did not quantify such differences nor explore them at the national, or sub-national, level.

We find no universal trends, with variation in age and sex patterns across specific bacteria-antibiotic combinations and across national and sub-national contexts, suggesting that cultural factors dominate biological ones. The main strengths of our analyses lie in the detailed BSI data used, as we were able to use one-year age bands, where trends may have been obscured in previous studies by high-level age groupings (e.g. (6,15,18,49)).

Focusing on two critical pathogens for bloodstream infections (*E. coli* (20.5%) and *S. aureus* (20.7%)) (50) and associated important resistances in Europe (41) and globally (51), we show substantial subnational and national variation, whilst demonstrating that there are age- and sex- related trends for specific bacteria-antibiotic combinations. Transmission of MRSA often occurs in healthcare settings (52) and increased contact with such settings with age could explain our observed often positive trend in resistance proportions by age. Whilst for aminopenicillin resistance in *E. coli* the contrasting dominant negative trend in resistance with age could be explained if, with age, more infections were endogenous and community-onset (see below).

Whilst resistance prevalence in many gram-negative bacteria often peaked at younger ages (as has been predicted for multidrug-resistant *M. tuberculosis* carriage (53)), we found little commonality in patterns between bacteria or within drug families. This suggests that the link between demographics and AMR is likely to be less driven by biological factors, but instead is driven more by cultural factors, as alternatively we might expect similar patterns of resistance within drug families across different bacteria. Contrasting this with the biological factors that can drive increased infection risk by age suggests that there is vital information in comparing and contrasting AMR prevalence in infection spatially by age and sex to improve intervention design and antimicrobial usage. For example, understanding trends in resistance by age could lead to improved understanding of the importance of antimicrobial use variation between ages and countries (54), healthcare contact and infection prevention control practices, and even microbiological sampling that could inform both data analysis for burden and evolution understanding as well as transmission intervention potential.

Our results could inform policy and practice in healthcare settings in a variety of ways. Firstly, understanding differences in age- and sex-related risks of infection with resistant bacteria could lead to more targeted empiric prescribing, tailored to the individual and setting, as has previously been suggested (15,17,55). This may be particularly important in older adults, that often experience more

severe consequences of bacterial infection (56). When considering empiric prescribing guidelines, it is vital to not just consider the impact of prescribing the most appropriate drug, but also the impact of delaying prescription until more information is available, which may have catastrophic consequences in severe infections ([Girard and Ely 2007](#)). Secondly, understanding the importance of demographic factors on AMR will support the collection and smart use of further data in this area. This is especially relevant due to the high levels of variation across settings that we identify, underpinning the need for local level infection data collection and policies. Whilst demographic data is often encouraged to be reported by countries, this is often not included in analyses, and its use is confounded by differences in the data sources and sampling practices (57). These differences, and the variation we found, highlight the need for reducing the reliance on estimates of AMR based on either single settings within a country or national averages, as done with large global estimation studies (49), as averaging across data collected from different study sites can reduce the accuracy and poorly reflect heterogeneity.

This is not only true for understanding AMR, but also BSI risks – sex-differences in incidence by age could give clues to targeting this large contributor to mortality that are not commonly explored or considered in bloodstream infection epidemiology (58). The clear higher BSI rate in men, apart from for *E. coli* infections in those aged 15-40, contrasts with the lack of clear sex effect in many of the resistance trends. The higher BSI levels in women aged 15-40 has been seen previously (59,60) and could reflect the higher urinary tract infection incidence in women (61) which are a common BSI source (62,63).

In addition to the direct implications of our findings on public health policy, understanding of the links between demographics and AMR will be foundational to a deeper understanding of acquisition routes of AMR. In our analysis we explored demographic trends across populations but are limited in our ability to understand the mechanisms behind these trends, where further research is required. One potential avenue for such research is to explore the source of the bacterium causing the bloodstream infection: endogenous following long-term carriage or recent transmission. Age- and sex-related patterns in bloodstream infection source will be influenced by many factors, such as levels of contact with healthcare systems (e.g. hospital stays, previous antibiotic prescriptions (55)), individual behaviour (e.g. causes for hospital admission, rate of contact with other individuals) and inherent biology (e.g. immunosenescence, likelihood of source being a urinary tract or wound infection), as well as varying by bacteria-antibiotic combination. Whilst the contribution of some of these factors have direct links to incidence by age (e.g. immunosenescence contributes to higher sepsis incidence with age (64)), linking these factors to proportion resistance by age is more complicated.

One theory linking the proportion of resistant infections with age is that older individuals are more likely to have weaker immune systems, and therefore are more likely to develop infections due to bacteria they are already colonised with and then enter the healthcare setting, as compared to younger individuals that would be relatively more likely to acquire a resistant bacterium through a transmission event within a healthcare setting. This would have implications for the proportion resistant by demographic characteristics for given bacteria and could be linked to changes in the microbiome with age (65). One of the most surprising species we detected patterns for was *Acinetobacter* species, with strong age-, sex- and subregion-related trends. This could be explained by young men being more likely to attend hospital for trauma compared to women (66), so if for this demographic population the key route to bloodstream infections is from wound infections due to bacteria (such as *Acinetobacter spp.*(67)) acquired in hospital, this could explain the differences we observed in resistant proportion. Differences in incidence and resistance proportion could also be explained by the demographics of those who travel to areas with higher prevalence of *Acinetobacter* species. Key to understanding the influence of the various factors on AMR is detailed knowledge at an individual level, as well as information on community vs hospital acquisition and antibiotic exposure, which we were unable to determine in this study. However, there are indications that for many

bacteria, hospital-acquired infections are likely to have higher resistance (24) so changing contact with healthcare would be an important avenue to explore. Exploiting this demographic link could also be used to tackle and determine the key drivers of known subregional variation in resistance prevalence (41). Our work therefore highlights the need for future research on the mechanisms of age- and sex-related AMR trends. In order to achieve this individual-patient level data, linked across primary and secondary care will be essential.

Our research has several limitations. Firstly, we were unable to account for co-morbidities and other syndromes of individuals, which may impact the age groups that are susceptible to different infections. For example, cystic fibrosis patients are known to be particularly susceptible to infections of *P. aeruginosa* (68), whilst also being correlated with the demographics of patients (69). Not including such aspects may particularly bias our work on the future burden of AMR, as the demographics of the syndromes will likely also change over time (69). This also highlights the need to take syndromes into account when prescribing antibiotics, as well as demographic factors, and to record such information alongside AMR data. Our analysis is only of European data, and not split by community or hospital-onset, and as such may not represent universal trends that could vary in other settings, in particular where demographic and healthcare distributions are substantially different.

In addition, the individuals included in this data set may be biased because of variation in whose samples are sent to be tested for resistance. This variation will depend on demographics and can be influenced by the age of the individual, the severity of infection and previous failed antibiotic use, and testing guidelines, among other factors. Understanding the decisions in sampling made by clinicians and other healthcare professionals is a vital area of future study and may account for some of the local level variation we have identified (57). Upstream of the sampling decision, it may also be influenced by healthcare seeking behaviour, for example women are more likely to seek healthcare than men (70), and this also varies by age and potentially by country. Variation in what within hospital settings samples are taken from (ICU, A&E etc.) may also explain some of the national and sub-national variation we observe and which we report, but need further country-specific information to explore, in our sensitivity analysis. By using data from TESSy, which contains only blood and cerebrospinal fluid isolates, likely representing the most serious types of bacterial infection (71) where the vast majority of infections will be hospitalised, these biases should be minimal. However this does not mean they are all sampled, and of those there are many samples will test negatively for infection (72).

In terms of the analysis and modelling in this paper, we chose to limit ourselves to a 'one-size-fits-all' approach, applying the same models to each bacteria-antibiotic combination. There is potential for models that are a better fit to the data for specific bacteria-antibiotic combinations, however this approach allowed us to compare model outputs across bacteria-antibiotic combinations, as well as reducing the complexity required. Lastly, we did not attempt to link AMR prevalence with mortality rates. This is because we did not have appropriate information to do this, with age-specific mortality rates and the impact of resistance on infection being hard to estimate, with variations in baselines used (e.g. associated vs attributable (49)). Recent estimates have found that data scarcity makes estimating relative risks of mortality by sub-groups or geographical setting difficult (18).

Future work estimating the burden of AMR and impact of interventions will need to account for these trends by age and sex to accurately capture burden. The complexity in trends in resistance prevalence by age and sex interact with the exponential increase in BSI incidence with age to mean that often, the elderly population, especially men, would still be expected to suffer more infections with resistant bacteria. How this collides with the global shift to older populations (2) and the impact this will have on public health burden as well as AMR spread should be a research priority.

In 2018, the WHO asked “Is the impact of AMR the same for everyone? Do any groups in society face greater or different risks of exposure to AMR or more challenges in accessing, using and benefiting from the information, services and solutions to tackle AMR? If yes, who, why and what can we do about it?” (27). In this paper we go some way to addressing these questions by quantifying how AMR prevalence in bloodstream infections across Europe varies by age and sex, as well as identifying variation at the local level. We show the substantial impacts of including age and sex on AMR, and therefore encourage their inclusion in future data collection and research studies, to improve health outcomes across the spectrum of AMR.

Acknowledgements

We are grateful for all the work done by the staff of the participating clinical microbiology laboratories and of the national healthcare services that provided data to EARS-Net. We also thank Dr Sam Abbot, Dr David Hodgson and Dr Tim Russel for discussing model fitting complexities with us.

The views and opinions of the authors expressed herein do not necessarily state or reflect those of ECDC. The accuracy of the authors' statistical analysis and the findings they report are not the responsibility of ECDC. ECDC is not responsible for conclusions or opinions drawn from the data provided. ECDC is not responsible for the correctness of the data and for data management, data merging and data collation after provision of the data. ECDC shall not be held liable for improper or incorrect use of the data.

References

1. WHO. 2021b. 'Antibiotic Resistance'. 2021. <https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance>. [Accessed 2023-02-22]
2. WHO 2021a. 'Ageing and Health'. 2021. <https://www.who.int/news-room/fact-sheets/detail/ageing-and-health>. [Accessed 2021-03-23]
3. Gavazzi G, Krause KH. Ageing and infection. *Lancet Infect Dis*. 2002 Nov;2(11):659–66.
4. WHO. 2020. 'GLASS | Global Antimicrobial Resistance Surveillance System (GLASS)'. WHO. World Health Organization. 2020. <http://www.who.int/glass/en/>. [Accessed 2023-02-23]
5. WHO. 2023. 'WHO GLASS Dashboard'. 2023. https://worldhealthorg.shinyapps.io/glass-dashboard/_w_ef0f2081/#!/. [Accessed 2023-02-23]
6. ECDC. 2023. 'Surveillance Atlas of Infectious Diseases'. 2023. <https://atlas.ecdc.europa.eu/public/index.aspx?Dataset=27&HealthTopic=4>. [Accessed 2023-02-23]
7. Centres For Disease Control and Prevention. 2023. 'Antibiotic Resistance | A.R. & Patient Safety Portal'. 2023. <https://arpsp.cdc.gov/profile/antibiotic-resistance?tab=antibiotic-resistance>. [Accessed 2023-02-23]
8. WHO Regional Office for Europe and Europe/European Centre for Disease Prevention and Control. 2022. 'Antimicrobial Resistance Surveillance in Europe 2022 – 2020 Data'. Copenhagen: WHO Regional Office for Europe; <https://www.ecdc.europa.eu/sites/default/files/documents/Joint-WHO-ECDC-AMR-report-2022.pdf> [Accessed 2023-02-16]
9. Kontula KSK, Skogberg K, Ollgren J, Järvinen A, Lyytikäinen O. Population-Based Study of Bloodstream Infection Incidence and Mortality Rates, Finland, 2004–2018. *Emerg Infect Dis*. 2021 Oct;27(10).
10. Gagliotti C, Högberg LD, Billström H, Eckmanns T, Giske CG, Heuer OE, et al. Staphylococcus aureus bloodstream infections: diverging trends of meticillin-resistant and meticillin-susceptible isolates, EU/EEA, 2005 to 2018. *Eurosurveillance*. 2021 Nov 18;26(46):2002094.
11. Thorlacius-Ussing L, Sandholdt H, Larsen AR, Petersen A, Benfield T. Age-Dependent Increase in Incidence of Staphylococcus aureus Bacteremia, Denmark, 2008–2015. *Emerg Infect Dis*. 2019 May;25(5):875–82.
12. Wilson J, Elgohari S, Livermore DM, Cookson B, Johnson A, Lamagni T, et al. Trends among pathogens reported as causing bacteraemia in England, 2004–2008. *Clin Microbiol Infect*. 2011 Mar 1;17(3):451–8.
13. Laupland KB, Lyytikäinen O, Søggaard M, Kennedy KJ, Knudsen JD, Ostergaard C, et al. The changing epidemiology of Staphylococcus aureus bloodstream infection: a multinational population-based surveillance study. *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis*. 2013 May;19(5):465–71.

14. OECD. 2018. 'Stemming the Superbug Tide: Just A Few Dollars More'. OECD publishing, Paris. <https://www.oecd.org/health/stemming-the-superbug-tide-9789264307599-en.htm>. [Accessed 2021-03-31]
15. Weber SG, Miller RR, Perencevich EN, Tolentino J, Meltzer D, Pitrak D, et al. Prevalence of antimicrobial-resistant bacteria isolated from older versus younger hospitalized adults: results of a two-centre study. *J Antimicrob Chemother*. 2009 Dec;64(6):1291–8.
16. Sivasankar S, Goldman JL, Hoffman MA. Variation in antibiotic resistance patterns for children and adults treated at 166 non-affiliated US facilities using EHR data. *JAC-Antimicrob Resist*. 2023 Feb;5(1):dlac128.
17. Swami SK, Banerjee R. Comparison of hospital-wide and age and location - stratified antibiograms of *S. aureus*, *E. coli*, and *S. pneumoniae*: age- and location-stratified antibiograms. SpringerPlus. 2013 Dec;2(1):63.
18. Mestrovic T, Aguilar GR, Swetschinski LR, Ikuta KS, Gray AP, Weaver ND, et al. The burden of bacterial antimicrobial resistance in the WHO European region in 2019: a cross-country systematic analysis. *Lancet Public Health*. 2022 Nov 1;7(11):e897–913.
19. Glynn JR, Moss PAH. Systematic analysis of infectious disease outcomes by age shows lowest severity in school-age children. *Sci Data*. 2020 Oct 15;7(1):329.
20. ReAct. 2020. 'ReAct Report: Antibiotic Resistance Affects Men and Women Differently – 2020'. <https://www.reactgroup.org/news-and-views/news-and-opinions/year-2020/new-react-report-antibiotic-resistance-affects-men-and-women-differently/>. [Accessed 2022-10-26]
21. Badura A, Feierl G, Pregartner G, Krause R, Grisold AJ. Antibiotic resistance patterns of more than 120 000 clinical *Escherichia coli* isolates in Southeast Austria, 1998–2013. *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis*. 2015 Jun;21(6):569.e1-7.
22. Badura A, Pregartner G, Holzer JC, Feierl G, Grisold AJ. Susceptibility of Austrian Clinical *Klebsiella* and *Enterobacter* Isolates Linked to Patient-Related Data. *Front Microbiol*. 2016;7:34.
23. Livermore DM, Nichols T, Lamagni TL, Potz N, Reynolds R, Duckworth G. Ciprofloxacin-resistant *Escherichia coli* from bacteraemias in England; increasingly prevalent and mostly from men. *J Antimicrob Chemother*. 2003 Dec 1;52(6):1040–2.
24. Sahuquillo-Arce JM, Selva M, Perpiñán H, Gobernado M, Armero C, López-Quílez A, et al. Antimicrobial Resistance in More than 100,000 *Escherichia coli* Isolates According to Culture Site and Patient Age, Gender, and Location. *Antimicrob Agents Chemother*. 2011 Mar;55(3):1222–8.
25. Nguyen HQ, Nguyen NTQ, Hughes CM, O'Neill C. Trends and impact of antimicrobial resistance on older inpatients with urinary tract infections (UTIs): A national retrospective observational study. *PloS One*. 2019;14(10):e0223409.
26. MacKinnon MC, McEwen SA, Pearl DL, Lyytikäinen O, Jacobsson G, Collignon P, et al. Increasing incidence and antimicrobial resistance in *Escherichia coli* bloodstream infections: a multinational population-based cohort study. *Antimicrob Resist Infect Control*. 2021 Sep 6;10(1):131.
27. WHO. 2018. 'TACKLING ANTIMICROBIAL RESISTANCE (AMR) TOGETHER Working Paper 5.0: Enhancing the Focus on Gender and Equity'. <https://www.who.int/antimicrobial->

- resistance/national-action-plans/AMRGenderEquityGuidance-Sept2018.pdf. [Accessed 2022-11-29]
28. Chua AQ, Verma M, Hsu LY, Legido-Quigley H. An analysis of national action plans on antimicrobial resistance in Southeast Asia using a governance framework approach. *Lancet Reg Health West Pac*. 2021 Feb;7:100084.
 29. Thomson K, Berry R, Robinson T, Brown H, Bambra C, Todd A. An examination of trends in antibiotic prescribing in primary care and the association with area-level deprivation in England. *BMC Public Health*. 2020 Aug 3;20:1148.
 30. Collignon P, Beggs JJ, Walsh TR, Gandra S, Laxminarayan R. Anthropological and socioeconomic factors contributing to global antimicrobial resistance: a univariate and multivariable analysis. *Lancet Planet Health*. 2018;2(9):e398–405.
 31. Auguet OT, Betley JR, Stabler RA, Patel A, Ioannou A, Marbach H, et al. Evidence for Community Transmission of Community-Associated but Not Health-Care-Associated Methicillin-Resistant *Staphylococcus Aureus* Strains Linked to Social and Material Deprivation: Spatial Analysis of Cross-sectional Data. *PLOS Med*. 2016 Jan 26;13(1):e1001944.
 32. European Centre for Disease Prevention and Control. 2022. 'Antimicrobial Consumption in the EU/EEA (ESAC-Net) - Annual Epidemiological Report for 2021'. Stockholm: ECDC. <https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-consumption-europe-2021>. [Accessed 2023-02-24]
 33. Curtis HJ, Walker AJ, Mahtani KR, Goldacre B. Time trends and geographical variation in prescribing of antibiotics in England 1998–2017. *J Antimicrob Chemother*. 2019 Jan 1;74(1):242–50.
 34. Eurostat. 2022. 'Fertility Statistics'. 2022. https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Fertility_statistics. [Accessed 2023-02-24]
 35. Eurostat. 2023. 'Surgical Operations and Procedures Statistics'. 21 February 2023. https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Surgical_operations_and_procedures_statistics. [Accessed 2023-02-24]
 36. Knight GM, Waterlow NR. ECDC data analysis for trends in AMR by age and sex [Internet]. 2023. Available from: https://github.com/gwenknight/ecdc_data_age_sex
 37. European Centre for Disease Prevention and Control,. 2022. 'The European Surveillance System (TESSy)'. 22 July 2022. <https://www.ecdc.europa.eu/en/publications-data/european-surveillance-system-tessy>. [Accessed 2022-01-13]
 38. 'External Quality Assessment of Laboratory Performance – European Antimicrobial Resistance Surveillance Network (EARS-Net), 2018'. 2019. European Centre for Disease Prevention and Control. 22 November 2019. <https://www.ecdc.europa.eu/en/publications-data/external-quality-assessment-laboratory-performance-european-antimicrobial-0>. [Accessed 2022-11-07]
 39. 'EARS-Net Reporting Protocol 2022'. 2022. European Centre for Disease Prevention and Control. 24 March 2022. <https://www.ecdc.europa.eu/en/publications-data/ears-net-reporting-protocol-2022>. [Accessed 2022-10-05]

40. European Committee on Antimicrobial Susceptibility Testing (EUCAST),. 2017. 'EUCAST Guidelines for Detection of Resistance Mechanisms and Specific Resistances of Clinical and/or Epidemiological Importance. Version 2'. Växjö, EUCAST. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/EUCAST_detection_of_resistance_mechanisms_170711.pdf [Accessed 2022-11-24]
41. Central Asian and European surveillance of Antimicrobial Resistance (CAESAR), and European Antimicrobial Resistance Surveillance Network (EARS-Net). 2023. 'Antimicrobial Resistance Surveillance in Europe - 2023'. <https://www.ecdc.europa.eu/en/publications-data/antimicrobial-resistance-surveillance-europe-2023>. [Accessed 2023-04-26]
42. Sharland M, Cappello B, Ombajo LA, Bazira J, Chitatanga R, Chuki P, et al. The WHO AWaRe Antibiotic Book: providing guidance on optimal use and informing policy. *Lancet Infect Dis*. 2022 Nov 1;22(11):1528–30.
43. Cassini A, Högberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. *Lancet Infect Dis*. 2019 Jan 1;19(1):56–66.
44. The World Bank Group. 2022. 'DataBank | The World Bank'. 2022. <https://databank.worldbank.org/home>. [Accessed 2022-10-19]
45. Bürkner PC. brms: An R Package for Bayesian Multilevel Models Using Stan. *J Stat Softw*. 2017 Aug 29;80:1–28.
46. Garcia A, Delorme T, Nasr P. Patient age as a factor of antibiotic resistance in methicillin-resistant *Staphylococcus aureus*. *J Med Microbiol*. 2017 Dec;66(12):1782–9.
47. Boyd LB, Atmar RL, Randall GL, Hamill RJ, Steffen D, Zechiedrich L. Increased fluoroquinolone resistance with time in *Escherichia coli* from >17,000 patients at a large county hospital as a function of culture site, age, sex, and location. *BMC Infect Dis*. 2008 Jan 15;8:4.
48. Ji Z, Han F, Meng F, Tu M, Yang N, Zhang J. The Association of Age and Antibiotic Resistance of *Helicobacter Pylori*. *Medicine (Baltimore)* [Internet]. 2016 Mar 3 [cited 2021 Mar 23];95(8). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4779009/>
49. Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *The Lancet* [Internet]. 2022 Jan 19 [cited 2022 Jan 25];0(0). Available from: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(21\)02724-0/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02724-0/fulltext)
50. Diekema DJ, Hsueh PR, Mendes RE, Pfaller MA, Rolston KV, Sader HS, et al. The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program. *Antimicrob Agents Chemother*. 2019 Jun 24;63(7):e00355-19.
51. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. *Lancet Infect Dis*. 2018 Mar;18(3):318–27.
52. Turner NA, Sharma-Kuinkel BK, Maskarinec SA, Eichenberger EM, Shah PP, Carugati M, et al. Methicillin-resistant *Staphylococcus aureus*: an overview of basic and clinical research. *Nat Rev Microbiol*. 2019 Apr;17(4):203–18.

53. Knight GM, McQuaid CF, Dodd PJ, Houben RMGJ. Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling. *Lancet Infect Dis*. 2019 Aug;19(8):903–12.
54. Mor A, Frøslev T, Thomsen RW, Oteri A, Rijnbeek P, Schink T, et al. Antibiotic use varies substantially among adults: a cross-national study from five European Countries in the ARITMO project. *Infection*. 2015 Aug;43(4):453–72.
55. Yelin I, Snitser O, Novich G, Katz R, Tal O, Parizade M, et al. Personal clinical history predicts antibiotic resistance of urinary tract infections. *Nat Med*. 2019 Jul;25(7):1143–52.
56. Esme M, Topeli A, Yavuz BB, Akova M. Infections in the Elderly Critically-Ill Patients. *Front Med*. 2019 Jun 6;6:118.
57. WHO. 2023a. 'Methodological Principles of Nationally Representative Surveys as a Platform for Global Surveillance of Antimicrobial Resistance in Human Bloodstream Infection.' Geneva: World Health Organization. [Accessed 2023-06-23]
58. Kern WV, Rieg S. Burden of bacterial bloodstream infection—a brief update on epidemiology and significance of multidrug-resistant pathogens. *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis*. 2020 Feb;26(2):151–7.
59. UK Health Security Agency. 2023. 'Enterococcus Spp. Bacteraemia: Voluntary Surveillance 2021'. 27 February 2023. <https://www.gov.uk/government/publications/enterococcus-spp-bacteraemia-voluntary-surveillance-2021>. [Accessed 2023-06-07]
60. Bonten M, Johnson JR, van den Biggelaar AHJ, Georgalis L, Geurtsen J, de Palacios PI, et al. Epidemiology of Escherichia coli Bacteremia: A Systematic Literature Review. *Clin Infect Dis*. 2021 Apr 1;72(7):1211–9.
61. Al-Badr A, Al-Shaikh G. Recurrent Urinary Tract Infections Management in Women. *Sultan Qaboos Univ Med J*. 2013 Aug;13(3):359–67.
62. Abernethy J, Guy R, Sheridan EA, Hopkins S, Kiernan M, Wilcox MH, et al. Epidemiology of Escherichia coli bacteraemia in England: results of an enhanced sentinel surveillance programme. *J Hosp Infect*. 2017 Apr;95(4):365–75.
63. UK Health Security Agency. 2022. 'Annual Epidemiological Commentary: Gram-Negative, MRSA, MSSA Bacteraemia and C. Difficile Infections, up to and Including Financial Year 2021 to 2022'. GOV.UK. 29 September 2022. <https://www.gov.uk/government/statistics/mrsa-mssa-and-e-coli-bacteraemia-and-c-difficile-infection-annual-epidemiological-commentary/annual-epidemiological-commentary-gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-up-to-and-including-financial-year-2021-to-2022>. [Accessed 2023-06-07]
64. Girard TD, Ely EW. Bacteremia and sepsis in older adults. *Clin Geriatr Med*. 2007 Aug;23(3):633–47, viii.
65. Bosco N, Noti M. The aging gut microbiome and its impact on host immunity. *Genes Immun*. 2021 Oct;22(5):289–303.
66. NHS. 2021. 'Hospital Admitted Patient Care Activity'. NHS Digital. 2021. <https://digital.nhs.uk/data-and-information/publications/statistical/hospital-admitted-patient-care-activity>. [Accessed 2023-06-21]

67. Chopra T, Marchaim D, Awali RA, Krishna A, Johnson P, Tansek R, et al. Epidemiology of Bloodstream Infections Caused by *Acinetobacter baumannii* and Impact of Drug Resistance to both Carbapenems and Ampicillin-Sulbactam on Clinical Outcomes. *Antimicrob Agents Chemother*. 2013 Dec;57(12):6270–5.
68. Lyczak JB, Cannon CL, Pier GB. Lung Infections Associated with Cystic Fibrosis. *Clin Microbiol Rev*. 2002 Apr;15(2):194–222.
69. Keogh RH, Tanner K, Simmonds NJ, Bilton D. The changing demography of the cystic fibrosis population: forecasting future numbers of adults in the UK. *Sci Rep*. 2020 Jun 30;10(1):10660.
70. Thompson AE, Anisimowicz Y, Miedema B, Hogg W, Wodchis WP, Aubrey-Bassler K. The influence of gender and other patient characteristics on health care-seeking behaviour: a QUALICOPC study. *BMC Fam Pract*. 2016 Dec;17(1):1–7.
71. Goto M, Al-Hasan MN. Overall burden of bloodstream infection and nosocomial bloodstream infection in North America and Europe. *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis*. 2013 Jun;19(6):501–9.
72. Ratzinger F, Dedeyan M, Rammerstorfer M, Perkmann T, Burgmann H, Makristathis A, et al. A risk prediction model for screening bacteremic patients: a cross sectional study. *PLoS One*. 2014;9(9):e106765.

Appendix S1: How demographic factors matter for antimicrobial resistance – quantification of the patterns and impact of variation in prevalence of resistance by age and sex.

Table of Contents

1. Abbreviations	2
2. Data cleaning.....	3
3. Incidence calculations.....	11
4. Population trends – 2000 to 2021	14
5. Model fitting.....	17

1. Abbreviations

ACISPP = *Acinetobacter spp*

ENCFAE = *Enterococcus faecalis*

ENCFAI = *Enterococcus faecium*

ESCCOL = *Escherichia coli*

KLEPNE = *Klebsiella pneumoniae*

PSEAER = *Pseudomonas aeruginosa*

STAAUR = *Staphylococcus aureus*

STRPNE = *Streptococcus pneumoniae*

#K = number of thousands

AMR = antimicrobial resistance

BSI = bloodstream infection

EARS-NET = European Antimicrobial Resistance Surveillance Network (EARS-Net)

ECDC = European Centre for Disease Prevention and Control

GLASS = Global Antimicrobial Resistance and Use Surveillance System

IQR = interquartile range

MRSA = methicillin resistant *S. aureus*

WHO = World Health Organisation

2. Data cleaning

Original data

The original data from the ECDC included 3,549,617 isolates with age, reporting country and different combinations of test results to a variety of antibiotics. This grouped into 510,816 unique combinations of year, age, pathogen, gender, antibiotic tested and country with a total of 9,855,100 antibiotic testing results (either susceptible “0” or resistant “1”) over 46 bacteria-antibiotic groupings. Samples were tested to a different combination of antibiotics: on average 2.7 antibiotic test results were conducted per sample. There were slightly fewer females in the data: 1,445,370 (45%) of isolates were from females.

The proportion of isolates in each age group (0-4, 5-19, 20-64, 65+) and by patient sex are reported in EARS-Net country summaries and on the ECDC Dashboard (e.g. of the 2019 report (1)).

Data overview

- (1) Laboratory code: There were 1755 unique laboratory codes in the data with a wide range of number of samples per laboratory: an average of 1803 [IQR: 47 - 2202]. No specimens were missing a laboratory code.
- (2) Antibiotics: Across the 24 different antibiotic resistance groupings (e.g. some to individual antibiotics, some to families such as macrolides, some to multiple resistance) over the whole dataset, most had more than 50,000 results (susceptible or resistant value), but three were outliers with fewer than 20,000.
- (3) Some antibiotic classifications were not to single antibiotics but were summary indicators of “multiple resistances” i.e. in the data a `1` indicated multi-resistance when resistance to a set combination of resistances was measured e.g. to macrolides and penicillin. This data was excluded as the aim here was to consider resistance to single antibiotics, not combinations. These “combined” resistance profiles were generated to look at levels of multi-resistant bacteria in the EARS-Net analysis (e.g. Table 3 in (1)).
- (4) Bacteria: Of the 7 bacteria in the dataset, all had >150,000 results apart from *Acinetobacter* species which had ~50,000. All bacteria were kept in the data.
- (5) Countries: Across countries, four countries had approximately a million isolates. There was a substantial decline across the other countries. 5 countries had fewer than 12,000 isolates. We did not exclude any country from the analysis.
- (6) Years: Across the 19 years (2002 – 2020), the earlier time points had fewer data (~65K results) compared to more than ~750K from 2016. This was distributed differently across different pathogens and so we did not explicitly exclude certain years. Instead, we focused our analysis on the final five years prior to the COVID-19 pandemic i.e. 2015-2019. Subsetting the data to this time period only removed the country Lithuania which had no linked gender data for this time period.

Missing data distributions

To determine if the missingness in the data was completely at random, we investigated the missingness by key variables (age, sex and susceptibility). We considered the pattern overall as we’d expect different denominator patterns for each bacteria-antibiotic, but also explored the proportion of missingness for each bacterial species and for the case study of *S. aureus*.

Over the whole dataset, there were a total of 1,902,271 individual records over the 2015-2019 time period, of which 6.0% were missing age only, 1.5% were missing sex only and 2.2% were missing both age and sex. To check for biases in missingness we compared the distribution of ages with those missing sex and those not missing sex (Figure 1A). We also compared the distribution of sex with those missing and not missing age (Figure 1B). In both cases differences were minimal. As a case study, we

ran the same analysis on just the *S. aureus* patients (Figure 2). To further confirm the minimality of differences a logistic regression was performed on those with missing gender information compared to those without missing information on the *S. aureus* subset, however these models did not reach convergence. This was also the case when looking at missingness in age. Therefore, as we could not investigate this further and the crude comparison showed minimal differences by missingness, imputation of missing data was not performed.




Figure 1: A) Density of individuals across age groups, for those individuals including and missing sex. B) Proportion and 95% CI of female individuals, subsetted for those including and missing age.




Figure 2: A) Density of individuals across age groups infected with *S.aureus*, for those individuals including and missing sex. B) Proportion and 95% CI of female individuals infected with *S.aureus*, subsetted for those including and missing age.

Not all samples were tested for each resistance type, and hence were coded as NA values in the data. The proportion of samples that were not tested for susceptibility ranged between 1.4% and 51.8%, depending on the bacteria-antibiotic combination (Table 1).

Table 1: Percentage of bacterial samples tested for resistance by bacteria and antibiotic.

Bacteria	Code in data		Antibiotic	Percentage of bacterial samples tested for antibiotic (%)
<i>Acinetobacter</i> species	acisp	amika_R	Amikacin	71.8
	acisp	aminogl_R	Aminoglycosides	96.9
	acisp	carbapen_R	Carbapenems	98.4
	acisp	fq_pseudo_R	Fluroquinolones	97.5
<i>Enterococcus faecalis</i>	encfae	aminopen_R	Aminopenicillins	93.7
	encfae	genta_high	High-level aminoglycoside	59.5
	encfae	vanco_R	Vancomycin	97.8
<i>Enterococcus faecium</i>	encfai	aminopen_R	Aminopenicillins	94.4
	encfai	genta_high	High-level aminoglycoside	57.5
	encfai	vanco_R	Vancomycin	98.3
<i>Escherichia coli</i>	esccol	amika_R	Amikacin	56.7
	esccol	aminogl_R	Aminoglycosides	97.8
	esccol	aminopen_R	Aminopenicillins	82.7

	esccol	carbapen_R	Carbapenems	96.0
	esccol	cefIII_entero_R	Third-generation cephalosporins	97.3
	esccol	fq_ent_R	Fluoroquinolones	98.3
	esccol	ureidopen_R	piperacillin-tazobactam	71.6
<i>Klebsiella pneumoniae</i>	klepne	amika_R	Amikacin	66.4
	klepne	aminogl_R	Aminoglycosides	97.6
	klepne	carbapen_R	Carbapenems	96.9
	klepne	cefIII_entero_R	Third-generation cephalosporins	98.0
	klepne	ert_R	Ertapenem	48.2
	klepne	fq_ent_R	Fluoroquinolone	98.5
	klepne	ureidopen_R	piperacillin-tazobactam	75.4
<i>Pseudomonas aeruginosa</i>	pseaer	amika_R	Amikacin	79.4
	pseaer	aminogl_R	Aminoglycoside	91.4
	pseaer	carbapen_R	Carbapenem	98.7
	pseaer	ceftaz_R	Ceftazidime	96.6
	pseaer	fq_pseudo_R	Fluoroquinolone	98.4
	pseaer	ureidopen_R	piperacillin-tazobactam	95.3
<i>Staphylococcus aureus</i>	staur	fq_staur_R	Fluoroquinolone	87.3
	staur	mrna_R	MRSA (oxacillin or ceftazidime)	97.4
	staur	rifamp_R	Rifampicin	77.8
<i>Streptococcus pneumoniae</i>	strpne	macrol_R	Macrolide	96.2
	strpne	penic_RI	Penicillins	93.3

We analysed the missingness of susceptibility test data for our case study MRSA, by age and sex. The distribution of ages between those missing and not missing susceptibility information followed the same trend and there were no differences in susceptibility missingness by sex (Figure 3).




Figure 3: A) Density of individuals across age groups infected with *S.aureus*, for those individuals including and missing susceptibility tests. B) Proportion and 95% CI of female individuals infected with *S.aureus*, subsetted for those including and missing susceptibility tests.

Final cleaned dataset

The final dataset filtered for data with (a) age and sex values, (b) for the time period 2015-2019, with (c) multi-resistance class groupings removed and (d) only those aged 1 or older, consisted of data on 17 bug-drug combinations across 8 bacteria (Table 2) and 29 countries (Table 3). Our main analysis therefore used a dataset consisting of a total of 3,881,140 measures of susceptibility consisting of 40% of the original dataset. The average proportion resistant was 30% (21% standard deviation) (across single year age and bug-drug combinations).

Table 2: AWaRE classification of bacteria antibiotics in data set.

Bacteria	Code in data		Antibiotic	AWaRE 2021 classification
<i>Acinetobacter species</i>	acispp	amika_R	Amikacin	Access
	acispp	aminogl_R	Aminoglycosides	Access + Watch
	acispp	carbapen_R	Carbapenems	Watch
	acispp	fq_pseudo_R	Fluroquinolones	Watch
<i>Enterococcus faecalis</i>	encfae	aminopen_R	Aminopenicillins	Access
	encfae	genta_high	High-level aminoglycoside	Access
	encfae	vanco_R	Vancomycin	Watch
<i>Enterococcus faecium</i>	encfai	aminopen_R	Aminopenicillins	Access
	encfai	genta_high	High-level aminoglycoside	Access
	encfai	vanco_R	Vancomycin	Watch
<i>Escherichia coli</i>	esccol	amika_R	Amikacin	Access
	esccol	aminogl_R	Aminoglycosides	Access + Watch
	esccol	aminopen_R	Aminopenicillins	Access
	esccol	carbapen_R	Carbapenems	Watch
	esccol	cefIII_entero_R	Third-generation cephalosporins	Watch + Reserve
	esccol	ert_R	Ertapenem	Watch
	esccol	fq_ent_R	Fluoroquinolones	Watch
	esccol	ureidopen_R	piperacillin-tazobactam	Watch
<i>Klebsiella pneumoniae</i>	klepne	amika_R	Amikacin	Access
	klepne	aminogl_R	Aminoglycosides	Access + Watch
	klepne	carbapen_R	Carbapenems	Watch
	klepne	cefIII_entero_R	Third-generation cephalosporins	Watch + Reserve
	klepne	ert_R	Ertapenem	Watch
	klepne	fq_ent_R	Fluoroquinolone	Watch
	klepne	ureidopen_R	piperacillin-tazobactam	Watch
<i>Pseudomonas aeruginosa</i>	pseaer	amika_R	Amikacin	Access
	pseaer	aminogl_R	Aminoglycoside	Access + Watch
	pseaer	carbapen_R	Carbapenem	Watch
	pseaer	ceftaz_R	Ceftazidime	Watch

	pseae	fq_pseudo_R	Fluoroquinolone	Watch
	pseae	ureidopen_R	piperacillin-tazobactam	Watch
<i>Staphylococcus aureus</i>	staur	fq_staur_R	Fluoroquinolone	Watch
	staur	mrsa_R	MRSA (oxacillin or cefoxitin)	Access
	staur	rifamp_R	Rifampicin	Watch
<i>Streptococcus pneumoniae</i>	strpne	macrol_R	Macrolide	Watch
	strpne	penic_RI	Penicillins	Access + Watch

Table 3: Number of susceptibility samples by bacteria-antibiotic (rows) and country (column) in cleaned dataset. Country labels are random anonymised three letter code used for this analysis only.

pathogen	name	FGI	YGW	UMV	VYQ	BKP	KXR	LKP	CIP	WLI	EJQ	IFY	AKX	FLV	PMS	BPQ	MUV	ANW	NSL	IGC	SEG	NAJ	ZYI	KVX	PUB	XTL	ABO	ZVM	QET	CGZ	TOTAL
acispp	amika_R	273	280	520	57	357	125	0	50	516	406	17	1828	817	1584	145	2	2943	42	247	47	116	14	1234	836	549	120	202	607	1364	15298
acispp	aminogl_R	391	284	494	193	357	1840	321	35	646	434	171	2071	833	1634	300	18	3777	44	246	45	597	148	1553	869	947	317	202	618	2789	22174
acispp	carbapen_R	390	335	530	193	357	1956	314	54	609	433	175	2086	841	1647	316	18	3737	37	253	47	596	149	1552	870	984	325	202	592	2731	22329
acispp	fq_pseudo_R	387	339	533	192	357	1936	330	41	605	432	175	2088	828	1631	324	18	3741	44	214	47	606	149	1536	865	980	321	202	613	2750	22284
encfae	aminopen_R	3555	1774	620	249	2631	12949	3015	314	457	4730	2078	9149	777	3205	1450	136	10803	309	264	149	4625	2515	3140	4327	657	4589	739	1130	9181	89517
encfae	genta_high	2085	1167	594	249	2629	8957	387	312	455	4380	0	5603	771	3209	1294	136	7456	297	369	146	3071	976	2947	4089	483	3998	722	1049	0	57831
encfae	vanco_R	3678	1773	613	249	2630	13353	2840	317	500	4845	2604	9775	777	3184	1470	136	10964	310	381	149	4618	2454	3224	4618	675	4690	739	1143	9286	91995
encfai	aminopen_R	2536	1148	335	176	1543	9103	3572	253	379	3158	1137	4056	404	1254	2083	79	6170	153	154	59	4256	978	1639	1990	403	2568	650	638	8800	59674
encfai	genta_high	1438	766	324	177	1543	6468	399	262	372	2880	0	2651	401	1261	1866	78	4311	145	227	59	3093	452	1619	1907	314	2275	640	543	0	36471
encfai	vanco_R	2632	1161	332	176	1544	9561	3653	277	397	3235	1470	4310	405	1259	2127	79	6269	152	233	59	4259	966	1773	2149	418	2597	650	675	9037	61855
esccol	amika_R	18388	15066	1260	245	4008	14111	0	2233	1319	32449	0	53632	4988	8539	12941	1	42897	2069	1221	1519	4668	1036	12021	26650	1060	19569	7341	4228	55710	349169
esccol	aminogl_R	26881	13796	1192	588	16301	77720	25320	3452	1321	34292	23422	53919	5205	8987	14900	1009	43786	2068	1361	1519	36880	18373	11465	28849	2483	32993	7343	4299	119115	618839
esccol	aminopen_R	26376	15758	1117	588	16288	78610	24923	2029	1301	33365	14064	54666	5234	8882	14738	1011	16809	2066	1365	1519	36871	18370	3859	28139	2166	395	7343	4249	110126	532227
esccol	carbapen_R	26336	15852	1242	587	7645	79072	23833	3028	1325	34235	24764	53202	5191	8665	14860	29	41942	2069	1364	1519	36862	18338	11566	28745	2555	32541	7343	4027	115881	604618
esccol	ceftill_entero_R	26794	15869	1274	588	16297	79110	23801	3446	1326	34268	24545	54555	5185	9095	14883	1011	43853	2069	1386	1519	36873	18378	12186	28942	2570	33291	7343	4290	107584	612331
esccol	ert_R	7525	7924	0	120	0	47580	622	2332	764	22040	2902	0	0	8195	10665	939	32612	1189	252	1191	2810	2116	4672	26887	780	7470	7323	3672	62280	264862
esccol	fq_ent_R	26955	15130	1273	588	16284	79044	25281	3413	1315	33618	24773	54668	5230	9064	14876	964	43422	2063	1367	1519	36876	18361	11049	28948	2556	32821	7291	4307	116592	619648
esccol	ureidopen_R	18247	13921	522	576	6398	77694	15463	1721	1323	31532	0	0	0	8579	0	938	42917	1757	281	1517	36003	16133	11230	25447	867	32589	7337	3906	73646	430544
klepne	amika_R	3952	2774	754	84	5610	2606	0	513	1085	8309	0	12484	1457	2941	1964	0	16263	419	606	558	1025	232	5100	11355	635	2636	1384	2157	10021	96924
klepne	aminogl_R	5717	2474	729	326	7054	14178	5898	779	1089	8664	3656	12645	1501	3074	2277	115	16583	419	705	558	6717	3832	4981	12008	1696	5970	1384	2186	21195	148410
klepne	carbapen_R	5734	2889	768	328	5654	14400	5599	688	1093	8662	3824	12484	1493	2988	2276	3	16192	419	705	557	6711	3827	5050	11981	1756	6313	1384	2079	20694	146551
klepne	ceftill_entero_R	5844	2906	769	328	7051	14401	5565	810	1095	8670	3799	12724	1484	3074	2274	115	16658	419	713	558	6715	3836	5173	12043	1780	6424	1384	2172	19408	148192
klepne	ert_R	1590	1358	0	38	0	8775	110	518	533	5979	525	0	0	2786	1599	108	12828	198	146	431	588	436	1898	11151	384	726	1378	1824	11155	67062
klepne	fq_ent_R	5895	2876	770	328	7049	14397	5894	780	1089	8572	3834	12738	1497	3049	2275	109	16555	419	702	558	6715	3831	4702	12057	1764	6321	1378	2183	20785	149122
klepne	ureidopen_R	4038	2585	325	321	5585	14209	3572	353	1089	8239	0	0	0	2879	0	108	16291	370	160	558	6522	3381	4880	10946	542	4788	1384	1933	13034	108092
pseae	amika_R	3305	1462	361	224	2068	5517	0	191	554	4245	0	8601	1060	3281	1111	1	8397	239	126	167	512	32	1833	5648	591	1020	759	1101	7562	59968
pseae	aminogl_R	3580	1301	339	230	2461	6849	2351	241	561	4656	1915	8762	1070	3361	1260	78	8640	233	126	167	3487	1139	1758	5698	621	2410	759	1106	10856	76015
pseae	carbapen_R	3601	1528	364	230	2462	6878	2279	241	559	4660	1918	8725	1071	3384	1259	78	8592	196	129	167	3481	1199	1791	5692	644	2423	759	1066	10679	76055
pseae	ceftaz_R	3314	1363	359	230	2461	6859	2263	183	557	4560	1912	8486	1023	3368	1228	77	8448	239	128	167	3466	1154	1845	5675	618	2406	759	982	10212	74342
pseae	fq_pseudo_R	3593	1456	364	230	2461	6879	2333	242	561	4657	1789	8728	1067	3376	1257	78	8581	239	129	167	3487	1203	1788	5679	640	2400	744	1106	10710	75944
pseae	ureidopen_R	3256	1398	358	230	2400	6774	2354	241	541	4511	1904	8444	1049	3342	1255	2	8359	221	122	167	3296	1117	1717	5661	596	2423	759	989	10243	73729
staur	fq_staur_R	12424	4987	1217	510	7827	41667	2504	1272	565	10311	10421	27109	2143	6931	5217	31	22425	788	1492	427	14788	5483	7703	15151	2589	12703	2760	2791	34369	258605
staur	mrsa_R	15415	5340	1247	504	9672	42892	9990	1439	603	10397	10869	27692	2163	6987	5492	422	22362	885	1436	427	15078	7427	8047	17238	2443	19365	2840	2794	35265	286731
staur	rifamp_R	14393	4061	682	311	9667	36896	2504	147	163	8363	10700	27808	1912	3936	4974	32	17347	707	1372	423	15021	3635	3296	10278	1826	12035	2840	2528	34728	232585
strpne	ceftill_strpne_R	2240	6836	121	56	1557	6115	0	307	0	3825	0	4624	595	836	1818	141	3325	205	171	106	5411	1833	1174	4488	324	2749	1396	139	6516	56908
strpne	fq_strpne_R	2279	6844	164	53	1659	6419	1439	244	0	3669	0	4624	669	744	962	1	3278	187	277	106	3149	0	1161	4352	383	3369	1432	51	11147	58662
strpne	macrol_R	2483	6844	175	54	1656	6622	3500	572	0	3811	3636	4624	675	796	1766	145	3222	206	275	103	7860	2212	1337	4541	332	4210	1333	153	16588	79731
strpne	penic_RI	2301	6844	178	42	1659	6568	3500	625	0	3832	32																			

3. Incidence calculations

The calculation of incidence used all data that had (a) age and (b) sex (male / female) recorded. Excluding those isolates without this information removed 4.8% or 7.1% of isolates respectively. Due to the overlap in missing data, the final data set included 91% of the original isolates (a total of 3,231,153 isolates).

The raw data can be used to calculate the number of *isolates* taken from patients of each age which can be standardised by the population in each age group. However, the network of contributing laboratories is not a population-based surveillance network – the number of isolates does not always reflect the total number of infections in a country. Therefore, in order to estimate the incidence of bloodstream infections by age we need to inflate the reported numbers by some indication of what proportion of the infections are captured i.e. the coverage.

Coverage complexity

The hurdles to understanding coverage are two-fold. Firstly, not all microbiology laboratories responsible for processing isolates are linked to the EARSS/EARS-Net network. In the ECDC AMR report of 2017 (2) (and previous years), the number of laboratories reporting at least one isolate to the EARSS/EARS-Net surveillance dataset is shown for the 2000-2016 period. The number of laboratories reporting is stable or increasing over this period, showing how coverage has improved.

However, the size and number of laboratories varies by country and hence it is hard to get an estimate for coverage or representativeness from this. Moreover, the overlapping hospital population catchment areas and movement of patients for care seeking means that the exact proportion of the population included in the data is highly difficult to assess. It requires local knowledge and will likely always be an approximation.

Hence, ECDC AMR reports since 2018 have asked countries to report an “Estimated population country coverage”. This is a self-assessed national coverage and sample representativeness value as estimated by the National Focal Points for AMR and/or Operational Contact Points for AMR (Table 2.1 in the 2018 report, Table 1 in the 2019 report, Table 2 in the 2020 report (3)). This is reported across all bacteria in the EARS-Net reports and shows a large variation between countries and some variation in time (Figure 4).




Figure 4: Combined estimated population coverage of the isolates reported in EARS-Net from the annual antimicrobial resistance surveillance reports (3) and estimates reported to Cassini et al. (shown with crosses).

It is likely that there is further variation in coverage or representativeness when comparing between bacteria. This is shown in data collected by Cassini and colleagues for their estimates of deaths and disability-adjusted life-years caused by antibiotic resistance bacteria in 2015 (4). Designated contact points in each Member State were given the possibility of providing an estimated “percentages of population covered” to give national population coverage (Table 3 in the Supplementary material of (4)). This showed that despite wide variation between countries (Figure 5), for 70% (21/30) of countries that reported values, the estimated coverage was the same across bacteria in 2015. Two countries had more than 50% variation between coverage –high coverage of *S. pneumoniae* (67%/87%) being an outlier against 18% coverage of other bacteria or 24% for others apart from *Acinobacter spp.* (8%) for France and Belgium respectively.




Figure 5: Estimated population coverage of EARS-Net from country experts as reported to the Cassini study (4).

The second hurdle is the variation in local sampling procedures – not just what patients might have their isolates sent to the laboratory but how many patients with an infection will even be sampled and where within the hospital and when. EARS-Net has attempted to address this by considering the blood culture rate (blood culture sets / 1,000 patient-days). This is complicated further by the varying country definitions of a blood culture set as well as a “patient day”. Thus, it is hard to use this indicator – in the ECDC reports it is seen as another factor to bear in mind when interpreting resistance trends and Cassini et al do not use it, after consideration, in their methods.

The added complexity of any variation in sampling by age or patient sex has no information to support any assumptions.

Only the values for Italy (Figure 4) gave a significant trend under a linear model testing for increasing coverage over time, and so it was decided to

- (1) use the country level values to inflate number of isolates where they exist for estimates of incidence
- (2) to use the last value available for a country as the value to inflate the data for total number of isolates in projections. Both the number of isolates that are likely to be reported to EARS-Net and the inflated totals per country are reported.

Our sensitivity analysis explored using the minimum coverage value instead of the last.

Cerebrospinal fluid isolates represent a small minority of the EARS-NET data (< 4% of all isolates, only rising to 6% for *S. pneumoniae*) and are likely to also have a BSI, so, following Cassini et al, we include them in our estimates of BSI.

4. Population trends – 2000 to 2021

The number of individuals in each age and sex group for the period of 2000-2021 was needed for the calculation of age-standardised incidence rates. Population sizes for 5yr age groupings were available from the World Bank DataBank (5) up to the age of 80 and then all adults were pooled. These are World Bank staff estimates using the World Bank's total population and age/sex distributions of the United Nations Population Division's World Population Prospects: 2019 Revision (6). The trends vary substantially by country (Figure 6) with an increase in the proportion in older ages present in most countries (Figure 7).




Figure 6: Population sizes by age group (5yr age bands represented by lowest age, x axis, e.g. plotted at age 0 for age band 0-5yo), sex (columns, f = female, m = male) and country (rows) for each year (colour) from the World Bank.




Figure 7: Proportion of population (y axis) in each age band (colour) over time (x axis) for each country (row) and each sex (column) from the World Bank.

5. Model fitting

Variables included

To determine whether country and laboratory level variation should be included in the model, we ran a variance-components model (using the R *glmer* functions) for MRSA, using this as a case study for the other bacteria-antibiotic combinations. Results showed that 33% of susceptibility variation lies between countries, 38% of susceptibility variations lies between laboratory ID and country combined. Figure 8 shows the variation across different laboratories and countries.




Figure 8: Predicted probability of resistance across (A) hospitals within a country and (B) laboratory ids over all countries.

Variable transformations

To achieve efficient model convergence, we transformed the input variables in our model to be on a similar scale. The transformations were as follows:

Model age <- Age / 100

Model age² <- Model age * Model age

Years were converted onto a scale of 0-1 corresponding to the years 2015-2019.

Fitting algorithm

We used the brms package in R to run our models using stan software (7). The algorithm used was no U-turn sampling (NUTS) which we ran for 3000 iterations for each model. We deemed models to not have converged if more than 1 divergent transition occurred. Bacteria-antibiotic combinations that did not converge were: *Escherichia coli* – Ertapenem, *Enterococcus faecalis* – aminopenicillins and *Enterococcus faecalis* – vancomycin. We therefore excluded these combinations from our analysis, as they did not converge and they were not considered key bacteria-antibiotic combinations: they were not included in recent ECDC analysis reports (e.g. (8)).

References

1. European Centre for Disease Prevention and Control [Internet]. 2020 [cited 2021 Apr 2]. Antimicrobial resistance in the EU/EEA (EARS-Net) - Annual Epidemiological Report for 2019. Available from: <https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2019>
2. European Centre for Disease Prevention and Control [Internet]. 2017 [cited 2022 Oct 26]. Antimicrobial resistance surveillance in Europe 2016. Available from: <https://www.ecdc.europa.eu/en/publications-data/antimicrobial-resistance-surveillance-europe-2016>
3. European Centre for Disease Prevention and Control. European Centre for Disease Prevention and Control. 2022 [cited 2022 Oct 26]. Annual Epidemiological Reports (AERs). Available from: <https://www.ecdc.europa.eu/en/publications-data/monitoring/all-annual-epidemiological-reports>
4. Cassini A, Högberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. *Lancet Infect Dis*. 2019 Jan 1;19(1):56–66.
5. the World Bank Group. DataBank | The World Bank [Internet]. 2022 [cited 2022 Oct 19]. Available from: <https://databank.worldbank.org/home>
6. World Population Prospects - Population Division - United Nations [Internet]. 2019 [cited 2021 Mar 12]. Available from: <https://population.un.org/wpp/>
7. Bürkner PC. brms: An R Package for Bayesian Multilevel Models Using Stan. *J Stat Softw*. 2017 Aug 29;80:1–28.
8. Central Asian and European surveillance of Antimicrobial Resistance (CAESAR), European Antimicrobial Resistance Surveillance Network (EARS-Net). Antimicrobial resistance surveillance in Europe - 2023 [Internet]. 2023 Apr [cited 2023 Apr 26]. Available from: <https://www.ecdc.europa.eu/en/publications-data/antimicrobial-resistance-surveillance-europe-2023>

Appendix S2: How demographic factors matter for antimicrobial resistance – quantification of the patterns and impact of variation in prevalence of resistance by age and sex.

Table of Contents

1. Additional results: subregion analysis	2
2. Additional results: Incidence	4
3. Additional results: total number of resistant infections by age	6
4. Additional results: Posterior estimates from model fit	7
5. Additional results: Modelling	9
6. Sensitivity analysis: data disaggregation by inpatient vs outpatient	12
7. Sensitivity analysis: data disaggregation by hospital unit type.....	14
8. Sensitivity analysis: incidence	17
9. Sensitivity Analysis: Priors.....	18
10. Sensitivity Analysis: Aged 0	19
11. Sensitivity Analysis: Model philosophy.....	20

1. Additional results: subregion analysis

We observed substantial variation by subregion, matching previously reported large variation in resistance prevalence (with a north-to-south and west-to-east gradient of resistance) (1) (Figure 1). Southern and Eastern generally had higher resistance prevalence with substantial age / gender differences in south + east especially for *Acinetobacter spp.* and MRSA patterns driven by south/east Europe, whilst for others the differences are less important e.g. for aminopenicillin resistance in *E. coli* (Figure 2). The patterns are still more similar within a bug-drug than across subregions: i.e. the same across subregions and then different between bug-drugs.




Figure 1: Trends in resistance prevalence vary by antibiotic, bacteria and demographic factors across the subregions of Europe. The proportion of isolates tested (y axis) that are resistant to each antibiotic (facet) within drug families (columns and colour) for each bacteria (row) is shown for all European data over 2015-2019 by age (x axis). Data is shown as points with number of samples indicated by size of point. Shaded areas are 95% confidence intervals around the LOESS fit line by gender (linetype and shade).




Figure 2: Zoomed in examples of how trends in resistance prevalence vary by antibiotic, bacteria and demographic factors across the subregions of Europe. The proportion of isolates tested (y axis) that are resistant to each antibiotic (facet) within drug families (columns and colour) for each bacteria (row) is shown for all European data over 2015-2019 by age (x axis). Data is shown as points with number of samples indicated by size of point. Shaded areas are 95% confidence intervals around the LOESS fit line by gender (linetype and shade).

2. Additional results: Incidence

The incidence of infection was calculated for all 29 countries in both datasets (population size and infection incidence). For this work we only included countries if they had reported data on the estimated coverage of these laboratories for any of the years this data was available: 2015, 2018-2020.

Country level data and analysis

These 28 countries were: "Austria", "Belgium", "Bulgaria", "Croatia", "Cyprus", "Czechia", "Denmark", "Estonia", "Finland", "France", "Germany", "Greece", "Hungary", "Iceland", "Ireland", "Italy", "Latvia", "Luxembourg", "Malta", "Netherlands", "Norway", "Poland", "Portugal", "Romania", "Slovak Republic", "Slovenia", "Spain", "Sweden" and "United Kingdom". Not all countries were included in each data point. There was substantial variation between countries.

What is similar between countries is that there appears to be a trend to increasing incidence rates over time for those with data from 2015-2020. This reflects trends seen in earlier reports for *S. aureus* across Europe from the same data for 2005-2018 (2) and earlier trends for all BSI across Europe for 2002-2008 (3). In individual countries increases have been seen in BSI e.g. due to *E. faecalis* in Switzerland 2013-2018 (4,5), in England and Wales 1990-1998 (6) or England 2004-2008 (7). We report this trend here but do not use it in our analyses.




Figure 3: Incidence of bloodstream infections per 100,000 population per year across European countries for 8 bacterial pathogens (panel) for multiple years (colour) and split by sex (solid line = female, dashed line = male). Shaded areas are 95% confidence intervals using a LOESS fit.

3. Additional results: total number of resistant infections by age

The combination of exponential increase in infection by age with the proportion resistant, leads to an exponential increase in the number of infections with resistant bacteria by age (Figure 4).




Figure 4: Total number of resistant infections by age in 2019 across Europe

4. Additional results: Posterior estimates from model fit

Table 1 shows all the fixed effect parameter values and their 95% posterior estimates.

Table 1: Posterior estimates for fixed effect parameter values. Blue indicates the 95% CI does not cross the null line. Shading matches Table 1 of main paper: orange shading indicates a positive significant effect and blue indicates a significant negative effect.

Bacteria	Antibiotic	year	age	age^2	sex(m)	Age:sex(m)
<i>Acinetobacter species</i>	Amikacin	-0.03 (-0.17 - 0.12)	4.58 (3.36 - 5.81)	-4.06 (-5.02 - -3.11)	0.22 (-0.08 - 0.53)	-0.14 (-0.61 - 0.33)
	Aminoglycosides	-0.16 (-0.29 - -0.03)	5.24 (4.25 - 6.23)	-4.33 (-5.13 - -3.53)	0.35 (0.08 - 0.61)	-0.22 (-0.62 - 0.19)
	Carbapenems	-0.12 (-0.26 - 0.01)	5.44 (4.30 - 6.57)	-4.85 (-5.74 - -3.95)	0.27 (-0.02 - 0.56)	-0.02 (-0.46 - 0.42)
	Fluroquinolones	-0.19 (-0.32 - -0.05)	5.87 (4.83 - 6.92)	-4.64 (-5.48 - -3.80)	0.42 (0.14 - 0.69)	-0.31 (-0.73 - 0.11)
<i>Enterococcus faecalis</i>	High-level aminoglycoside	-0.40 (-0.46 - -0.34)	1.42 (0.80 - 2.03)	-1.14 (-1.61 - -0.67)	0.11 (-0.07 - 0.29)	-0.05 (-0.30 - 0.20)
	Vancomycin	-0.41 (-0.67 - -0.16)	4.24 (1.70 - 6.79)	-3.58 (-5.59 - -1.57)	0.66 (-0.02 - 1.33)	-0.96 (-1.93 - 0.00)
	Aminopenicillins	0.10 (0.02 - 0.18)	4.29 (3.48 - 5.09)	-4.48 (-5.06 - -3.89)	-0.07 (-0.30 - 0.16)	0.12 (-0.20 - 0.44)
	High-level aminoglycoside	-0.33 (-0.40 - -0.25)	2.12 (1.39 - 2.85)	-1.97 (-2.56 - -1.38)	-0.04 (-0.24 - 0.17)	0.07 (-0.22 - 0.36)
<i>Escherichia coli</i>	Amikacin	0.04 (-0.08 - 0.17)	-0.95 (-2.04 - 0.14)	1.10 (0.25 - 1.95)	0.45 (0.12 - 0.78)	-0.21 (-0.67 - 0.24)
	Aminoglycosides	-0.05 (-0.07 - -0.02)	0.35 (-0.02 - 0.72)	0.13 (-0.08 - 0.35)	0.49 (0.41 - 0.57)	-0.34 (-0.45 - -0.23)
	Aminopenicillins	-0.08 (-0.10 - -0.07)	-0.36 (-0.58 - -0.14)	0.35 (0.22 - 0.49)	0.42 (0.37 - 0.48)	-0.41 (-0.48 - -0.34)
	Carbapenems	1.74 (1.42 - 2.05)	-3.23 (-5.37 - -1.09)	1.26 (-0.50 - 3.02)	0.78 (0.16 - 1.40)	-0.47 (-1.34 - 0.41)
	Fluroquinolones	-0.04 (-0.06 - -0.02)	1.35 (1.02 - 1.68)	-0.40 (-0.57 - -0.23)	0.72 (0.66 - 0.78)	-0.42 (-0.50 - -0.33)
	Third-generation cephalosporins	0.05 (0.03 - 0.08)	0.50 (0.10 - 0.90)	0.16 (-0.05 - 0.37)	0.56 (0.49 - 0.64)	-0.35 (-0.45 - -0.25)
	piperacillin-tazobactam	-0.14 (-0.18 - -0.10)	-0.01 (-0.45 - 0.42)	0.31 (0.00 - 0.63)	0.55 (0.44 - 0.67)	-0.48 (-0.63 - -0.33)
<i>Klebsiella pneumoniae</i>	Amikacin	-0.13 (-0.25 - -0.02)	1.52 (0.49 - 2.55)	-1.88 (-2.65 - -1.11)	0.20 (-0.05 - 0.45)	-0.08 (-0.45 - 0.30)
	Aminoglycosides	-0.13 (-0.18 - -0.09)	-0.07 (-0.57 - 0.43)	-0.50 (-0.83 - -0.17)	0.12 (0.00 - 0.24)	0.23 (0.06 - 0.40)

	Carbapenems	0.49 (0.39 - 0.58)	2.33 (1.21 - 3.45)	-3.31 (-4.00 - -2.61)	0.37 (0.15 - 0.60)	-0.30 (-0.63 - 0.02)
	Ertapenem	0.47 (0.36 - 0.58)	2.69 (1.69 - 3.69)	-3.13 (-3.86 - -2.40)	0.27 (0.02 - 0.52)	-0.17 (-0.53 - 0.20)
	Fluoroquinolones	0.14 (0.09 - 0.18)	0.84 (0.38 - 1.30)	-0.96 (-1.26 - -0.66)	0.14 (0.03 - 0.25)	0.22 (0.06 - 0.37)
	Third-generation cephalosporins	0.04 (0.00 - 0.08)	-0.13 (-0.59 - 0.32)	-0.43 (-0.73 - -0.13)	0.15 (0.05 - 0.26)	0.20 (0.04 - 0.35)
	piperacillin-tazobactam	0.12 (0.07 - 0.17)	0.84 (0.36 - 1.32)	-1.22 (-1.60 - -0.85)	0.09 (-0.04 - 0.22)	0.20 (0.01 - 0.38)
<i>Pseudomonas aeruginosa</i>	Amikacin	-0.25 (-0.36 - -0.13)	1.74 (0.79 - 2.70)	-2.69 (-3.49 - -1.88)	0.07 (-0.20 - 0.35)	0.07 (-0.35 - 0.50)
	Aminoglycosides	-0.34 (-0.42 - -0.26)	1.79 (1.14 - 2.44)	-2.39 (-2.94 - -1.84)	0.11 (-0.08 - 0.30)	0.06 (-0.23 - 0.35)
	Carbapenems	-0.12 (-0.18 - -0.05)	2.10 (1.53 - 2.66)	-3.52 (-3.98 - -3.05)	0.01 (-0.15 - 0.16)	0.10 (-0.14 - 0.34)
	Ceftazidime	-0.04 (-0.11 - 0.03)	1.25 (0.63 - 1.86)	-2.21 (-2.70 - -1.72)	0.05 (-0.11 - 0.22)	0.06 (-0.19 - 0.31)
	Fluoroquinolone	-0.01 (-0.07 - 0.05)	2.22 (1.65 - 2.78)	-2.59 (-3.04 - -2.14)	-0.02 (-0.18 - 0.14)	0.25 (0.01 - 0.48)
	piperacillin-tazobactam	-0.08 (-0.14 - -0.01)	1.21 (0.63 - 1.79)	-2.17 (-2.63 - -1.71)	0.05 (-0.11 - 0.21)	0.04 (-0.20 - 0.28)
<i>Staphylococcus aureus</i>	Fluoroquinolone	-0.38 (-0.41 - -0.34)	0.99 (0.46 - 1.52)	0.35 (0.08 - 0.63)	-0.26 (-0.36 - -0.16)	0.50 (0.37 - 0.64)
	MRSA (oxacillin or ceftoxitin)	-0.34 (-0.38 - -0.30)	-0.75 (-1.35 - -0.14)	1.04 (0.78 - 1.31)	-0.30 (-0.40 - -0.21)	0.55 (0.41 - 0.68)
	Rifampicin	-0.21 (-0.35 - -0.06)	4.06 (2.78 - 5.34)	-3.81 (-4.81 - -2.81)	0.47 (0.13 - 0.81)	-0.52 (-1.01 - -0.03)
<i>Streptococcus pneumoniae</i>	Macrolide	-0.10 (-0.18 - -0.03)	-2.77 (-3.21 - -2.33)	2.85 (2.50 - 3.21)	0.06 (-0.07 - 0.19)	-0.14 (-0.33 - 0.06)
	Penicillins	0.10 (0.02 - 0.18)	-3.34 (-3.82 - -2.87)	2.93 (2.54 - 3.31)	-0.04 (-0.18 - 0.10)	0.07 (-0.13 - 0.28)

5. Additional results: Modelling

Our results also allow us to analyse the variation in age effect across countries for bacteria-antibiotic combinations, and we see little country-level patterns (Figure 5). As in, there is no trend for similar age-associations across bacteria-antibiotic within a country. The impact of age across different countries is correlated for some bacteria-antibiotic combinations, such as some *S. aureus* and *E. coli* resistances (Figure 6). We also look at the magnitude of the age effect across sub-regions and bacteria-antibiotic, by ranking each country by the magnitude of effect for each bacteria-antibiotic over ages 1-100, and summing across bacteria-antibiotic combinations. Investigating these by subregion show stark differences, with a higher magnitude effect of age in Southern / Eastern Europe than in Northern / Western Europe (Figure 7).




Figure 5: Country level age effect (difference in proportion resistant between ages 1 and 100 with 95% quantiles) by bacteria- antibiotic combination. Country labels are random anonymised three letter code used for this analysis only.




Figure 6: Changes in proportion for ages 1-100 by country (x axis) and sex (colour). Country labels are random anonymised three letter code used for this analysis only.




Figure 7: Combined ranking across bacteria-antibiotics for the magnitude of the age effects between ages 1 and 100. Country labels are random anonymised three letter code used for this analysis only.

6. Sensitivity analysis: data disaggregation by inpatient vs outpatient

Background

The original dataset includes a category of “Patient type” which recorded whether the patient at the moment the sample was taken was admitted in a hospital (“INPAT”, inpatient), or not (“OUTPAT”, outpatient). Patients that go to the hospital for dialysis or other types of day hospital care are classified as other (“o” in the data) or “unknown”.

This category could be used as a proxy for the important definition of community- vs hospital-acquired infection as the data is on the first blood and/or cerebrospinal fluid isolate from a patient. However, the standard definition splits the above classification based on the first 48hrs of patient care. Hence, some of the “inpatient” samples here will be officially “community acquired” (taken when the patient has officially been admitted but before they have been in hospital < 48hrs) (8). We therefore cannot directly correlate this patient type with hospital vs community. Moreover, not all countries report this distinction – the UK has “unknown” for all isolates.

Exploring the data pooled across all countries with data, reveals the same age-dependent incidence curve for all bacteria across patient type where substantial data exists i.e. for inpatient and outpatient classifications and not “other” (Figure 8). Incidence is lower in outpatients as would be expected. Similar patterns can be seen for individual countries and across sexes as seen without the patient type split. However, this disaggregation also showed certain countries had substantially more isolates from outpatients. This likely reflects differences in healthcare processes and data coding.

Conclusions

The similarity of the high-income healthcare settings across Europe suggest that the above variations may be due to country level differences (“cultural factors”) in sampling and reporting rather than actual differences in bloodstream infection incidence by patient type. Hence, we have not explored resistance prevalence further by these patient types without further information on sample collection by country.




Figure 8: Impact of patient type (inpatient = INPAT, outpatient = OUTPAT or Other) on incidence of bloodstream infection for different bacterial types (colour) for 2019 for females (left) and males (right).

7. Sensitivity analysis: data disaggregation by hospital unit type

Background

The dataset included a category of “Hospital unit type” which recorded the hospital unit within which the patient was when the sample was taken.

The Hospital Unit Types in data are:

ED = Emergency Department, ICU = Intensive Care Unit, INFECT = Infectious Disease Ward, INTMED = Internal Medicine, O = Other, OBGYN = Obstetrics/Gynecology, ONCOL = Haematology/Oncology, PEDS = Pediatrics/neonatal, PEDSICU = Pediatrics/neonatal ICU, PHC = Primary Health Care, SURG = Surgery, UNK = Unknown, URO = Urology Ward

Data description

Most were internal medicine (“INTMED”, 27%) or “Unknown” (21%), followed by Emergency Department (“ED”, 14%), the “ICU” (11%) and Surgery (“SURG”, 8%).

The distribution varied substantially by country – with one country have up to 53% of isolates reported as unknown, whilst another had the up to 45% as “Internal medicine” .

The age / sex distribution of incidence results across hospital unit types and further over countries are basically the same as across all data – there is an age association, with *E. coli* being the dominant bacteria (Figure 9). There seem some issues with the paediatric data (PEDS / PEDSICU) data with some isolates having older age associated with them. The data for oncology (“ONCOL”) suggests there may be some survival bias effects (Figure 9). *S. aureus* has the second highest infection incidence across all hospital unit types except for urology (“URO”) where other bacteria have relatively equal infection incidence levels which makes sense. The data from obstetrics and gynaecology (“OBGYN”) emphasises the importance of childbirth as a risk factor for women, though with relatively low rates.

The distribution of infection incidence emphasises the above patterns showing for women aged 15-40 approximately 20% of the recorded bloodstream infections are linked to stays in the obstetrics and gynaecology departments (Figure 10). In men of this age, there is a larger contribution of infections in the ICU.




Figure 9: Total incidence of infection by age (x axis) and sex (columns) over all countries for different hospital unit types (rows) and bacteria (colours) in 2019. ED = Emergency Department, ICU = Intensive Care Unit, INFECT = Infectious Disease Ward, INTMED = Internal Medicine, O = Other, OBGYN = Obstetrics/Gynecology, ONCOL = Haematology/Oncology, PEDS = Pediatrics/neonatal, PEDSICU = Pediatrics/neonatal ICU, PHC = Primary Health Care, SURG = Surgery, UNK = Unknown, URO = Urology Ward




Figure 10: Distribution of infection incidence by hospital unit type (colour) across age (x axis) and sex (panels across Europe). ED = Emergency Department, ICU = Intensive Care Unit, INFECT = Infectious Disease Ward, INTMED = Internal Medicine, O = Other, OBGYN = Obstetrics/Gynecology, ONCOL = Haematology/Oncology, PEDS = Pediatrics/neonatal, PEDSICU = Pediatrics/neonatal ICU, PHC = Primary Health Care, SURG = Surgery, UNK = Unknown, URO = Urology Ward

Conclusions

The similarity of the high-income healthcare settings across Europe suggest that the above variations may be due to country level differences (“cultural factors”) in sampling and reporting rather than actual differences in bloodstream infection incidence by hospital unit type. Hence, we have not explored resistance prevalence further by these hospital unit types without further information on sample collection by country.

8. Sensitivity analysis: incidence

Using the minimum (instead of the actual reported or estimated coverage in 2019) estimates of the population coverage across the 2015-2019 data and estimates did not affect the sex and age patterns (Figure 11). The number of infections did increase substantially, as would be expected as coverage has been increasing for many countries, and also infections from countries that did not have coverage estimates for 2019 would be included if they had estimates for other years. On average, across all countries and years, the incidence was increased by ~38%, with similar increases for both sexes.




Figure 11: Incidence of bloodstream infections calculated using the minimum reported coverage estimates for surveillance per 100,000 population in 2019 across European countries for 8 bacterial pathogens split by (A) sex and bacteria for the first 50yrs of life and (B) sex (panel) and bacteria (colour) lifelong. Shaded areas are 95% confidence intervals using a LOESS fit. Infections in individuals younger than 0 are excluded, and those aged 80 and older are pooled into the 80yr data point. of bloodstream infections per 100,000 population per year across European countries for 8 bacterial pathogens (panel) for multiple years (colour) and split by sex (solid line = female, dashed line = male). Shaded areas are 95% confidence intervals using a LOESS fit.

9. Sensitivity Analysis: Priors

In our main paper models we had flat priors on all fixed effect variable parameters. In order to test the strength of our conclusions, we reran the MRSA model including regularising priors of $normal(0,1)$ for all the fixed effect variables. We chose MRSA to run our sensitivity analysis, as this was one of the case studies in the main manuscript. Results showed no effect of the regularising priors on the estimated posterior parameters (Figure 12).




Figure 12: Parameter comparisons for sensitivity analysis including regularising priors. Points indicate the mean of the posterior estimate, with lines indicating the 95%CI.

10. Sensitivity Analysis: Aged 0

In our main analysis we excluded infants aged 0 from the data, due to large differences in their immune system and infection mechanisms. To test the impact of this, we reran the model for MRSA including individuals aged 0. We found no difference in the posterior parameter estimates for the fixed effect model variables (Figure 13A). Moreover, no substantial differences were seen in the random country level effects of age (Figure 13B).




Figure 13: Parameter comparisons for sensitivity analysis including data from infants aged 0. Points indicate the mean of the posterior estimate, with lines indicating the 95%CI.

11. Sensitivity Analysis: Model philosophy

Whilst our main model used a Bayesian approach, where model variables that had no impact would have a parameter variable centred around 0, here we present a model comparison approach, for an example bacteria-antibiotic combination. In this approach, our base model (model A) did not account for sex or age impacts on resistance, but included a covariate for year, as well as random intercept effects for country and laboratory code (Equations 1:2). Our age model (model B) included additional covariates age, age-squared and a random covariate effect of age by country (Equations 3:4). This reflects the potential for age trends to be different across country due to differing policy and prescription patterns. Model C was the same as the base model, but additionally included a sex covariate (Equations 5:6). Model D was the complete model, including both age and sex terms, as in the main paper. Differences between the base model and subsequent models are shown in bold.

Model A	$y_{c,l,i} \sim \text{Binomial}(n_{c,l,i}, p_{c,l,i})$	(1)
	$p_{c,l,i} = \beta_0 + \beta_t * t_i + v_c + u_{c,l} + \epsilon_{c,l,i}$	(2)

Where y is the resistance variable, taking a value of 0 or 1, n is the number of samples and p the probability of the sample being found to be resistant. The subscripts c , l and i denote country, laboratory code and grouping level. Recall that for each bacteria-antibiotic combination, our data consisted of multiple groupings of individual samples of a bacterium tested for resistance to that antibiotic. Each grouping i had a unique combination of country (c), laboratory code (l), sex, age and year of sample and hence a linked number of samples (n) and proportion resistant (p). β_0 is the overall intercept, β_t is slope coefficient for time and t is year. $\epsilon_{c,l,i}$ is the residual error, $u_{c,l}$ is the level-2 random error on laboratory code and v_c is the level-3 random error on country.

Model B	$y_{c,l,i} \sim \text{Binomial}(n_{c,l,i}, p_{c,l,i})$	(3)
	$p_{c,l,i} = \beta_0 + \beta_t * t_i + \beta_a * \text{age}_i + \beta_{a^2} * \text{age}_i^2 + v_c + v_{ca} * \text{age}_i + u_{c,l} + \epsilon_{c,l,i}$	(4)

Where β_a is the age effect coefficient, β_{a^2} is the age squared effect coefficient and v_{ca} is the country level age effect coefficient.

Model C	$y_{c,l,i} \sim \text{Binomial}(n_{c,l,i}, p_{c,l,i})$	(5)
	$p_{c,l,i} = \beta_0 + \beta_t * t_i + \beta_g * \text{gender}_i + v_c + u_{c,l} + \epsilon_{c,l,i}$	(6)

Where β_g is the sex effect coefficient.

Model D	$y_{c,l,i} \sim \text{Binomial}(n_{c,l,i}, p_{c,l,i})$	(7)
	$p_{c,l,i} = \beta_0 + \beta_t * t_i + \beta_a * \text{age}_i + \beta_{a^2} * \text{age}_i^2 + \beta_g * \text{gender}_i + \beta_{ag} * \text{age}_i * \text{gender}_i + v_c + v_{ca} * \text{age}_i + u_{c,l} + \epsilon_{c,l,i}$	(8)

Where β_{ag} is the sex and age interaction coefficient.

We ran this set of models for MRSA (coefficient estimates in Figure 14A). Leave-one-out cross validation (approximated by the Pareto smoothed importance-sampling method) (LOOIC) and the widely applicable information criterion (WAIC) were used to compare the predictive ability of the models.

Due to model nesting, we compared A-B-D and A-C-D separately. Including age in the base model A had a large impact on the LOOIC (Figure 14B, Model B vs Model A), and adding sex on top of that resulted an additional small improvement (Model D vs Model B). However, adding sex to the base model did not improve the LOOIC (Figure 14C, Model C vs Model A). Adding in age as well as sex had significant improvements on the LOOIC (Model D vs Model C). These results indicate that Model D, the one used in our main analysis, would be chosen as the best model to use in the model comparison approach for MRSA.




Figure 14: Philosophical sensitivity analysis. A) Comparison of posterior parameter values across models. B) LOOIC for nested models with age. C) LOOIC for nested models with gender.

References

1. Central Asian and European surveillance of Antimicrobial Resistance (CAESAR), European Antimicrobial Resistance Surveillance Network (EARS-Net). Antimicrobial resistance surveillance in Europe - 2023 [Internet]. 2023 Apr [cited 2023 Apr 26]. Available from: <https://www.ecdc.europa.eu/en/publications-data/antimicrobial-resistance-surveillance-europe-2023>
2. Gagliotti C, Högberg LD, Billström H, Eckmanns T, Giske CG, Heuer OE, et al. Staphylococcus aureus bloodstream infections: diverging trends of meticillin-resistant and meticillin-susceptible isolates, EU/EEA, 2005 to 2018. *Eurosurveillance*. 2021 Nov 18;26(46):2002094.
3. de Kraker MEA, Jarlier V, Monen JCM, Heuer OE, van de Sande N, Grundmann H. The changing epidemiology of bacteraemias in Europe: trends from the European Antimicrobial Resistance Surveillance System. *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis*. 2013 Sep;19(9):860–8.
4. Piezzi V, Gasser M, Atkinson A, Kronenberg A, Vuichard-Gysin D, Harbarth S, et al. Increasing proportion of vancomycin-resistance among enterococcal bacteraemias in Switzerland: a 6-year nation-wide surveillance, 2013 to 2018. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2020 Sep;25(35).
5. Buetti N, Atkinson A, Marschall J, Kronenberg A, Swiss Centre for Antibiotic Resistance (ANRESIS). Incidence of bloodstream infections: a nationwide surveillance of acute care hospitals in Switzerland 2008-2014. *BMJ Open*. 2017 Mar 21;7(3):e013665.
6. Reacher MH, Shah A, Livermore DM, Wale MC, Graham C, Johnson AP, et al. Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. *BMJ*. 2000 Jan 22;320(7229):213–6.
7. Wilson J, Elgohari S, Livermore DM, Cookson B, Johnson A, Lamagni T, et al. Trends among pathogens reported as causing bacteraemia in England, 2004-2008. *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis*. 2011 Mar;17(3):451–8.
8. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. *Am J Infect Control*. 1988 Jun 1;16(3):128–40.